Kits, devices, and methods for detecting ovarian tumors

Abstract

To provide a kit or a device for detection of ovarian tumor, and a detection method.SOLUTION: The present invention provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an ovarian tumor detection kit or device comprising a nucleic acid capable of specifically binding to a specific miRNA or a complementary strand thereof, which is used for testing whether a subject suffers from an ovarian tumor, and a method for detecting an ovarian tumor comprising measuring the expression level of the miRNA using said nucleic acid. [Background Art]

[0002] The ovary is a female-specific reproductive organ that produces eggs, and one ovary is located on each side of the uterus. The fallopian tube is a duct through which an egg released from the ovary travels to the uterus, where a fertilized egg implants and develops into a fetus. The ovary also has the function of secreting the female hormones estrogen and progesterone. The ovary is considered an organ prone to tumor development, and ovarian tumors are broadly classified into surface epithelial-stromal tumors, sex cord-stromal tumors, and germ cell tumors based on their origin. Ovarian tumors are classified into benign, borderline malignant, and malignant according to their degree of malignancy; borderline malignant and malignant ovarian tumors are referred to as ovarian cancer. According to data disclosed by the Cancer Control Information Center of the National Cancer Center Japan, a national research and development agency, the incidence of ovarian cancer in Japan was 9,384 cases in 2012, meaning 1 in 87 Japanese women suffers from the disease, and the number of deaths from ovarian cancer reached 4,840 in 2014. In the United States, it is said that 1 in 75 women will develop ovarian cancer. The estimated number of new ovarian cancer cases in the United States in 2017 was as high as 22,440, and approximately 14,080 of those cases are expected to result in death.

[0003] The stage of ovarian and fallopian tube cancer is determined by whether the tumor is unilateral or bilateral, and by the presence and size of intraperitoneal dissemination, lymph node metastasis, and distant metastasis. It is classified into stages IA, IB, IC (IC1, IC2, IC3), IIA, IIB, IIIA1, IIIA2, IIIB, IIIC, IVA, and IVB. The 5-year relative survival rate for ovarian cancer depends heavily on the stage of the cancer, with reports indicating a 92% survival rate when the cancer is localized, 73% when the cancer is in the surrounding area, and 29% when distant metastasis is present. Therefore, early detection of ovarian cancer leads to improved survival rates, and there is a strong need for means to enable early detection.

[0004] While surgical treatment is the primary method for treating ovarian cancer, drug therapy may be used in combination depending on the stage of progression, metastasis, overall health, and classification of the cancer. In particular, if ovarian cancer is detected as an early stage I, it may be possible to remove only the ovary and fallopian tube on the side where the cancer was found, rather than the entire uterus, ovaries, and fallopian tube, thus preserving the woman's future ability to have children.

[0005] Furthermore, early-stage ovarian cancer and benign ovarian tumors often have no symptoms, and even advanced ovarian cancer often only presents with common symptoms that can be caused by other factors, such as abdominal bloating and pain, making it difficult to detect ovarian tumors based on subjective symptoms alone. Although many studies have been conducted on screening tests for ovarian cancer, no significant results have been achieved, and it is believed that only two methods are actually usable as screening tests: transvaginal ultrasound and the blood marker CA-125 test. Secondary screening tests for ovarian cancer include imaging tests such as ultrasound, CT scans, MRI, and PET / CT.

[0006] Although still in the research stage, as shown in Patent Documents 1-4 and Non-Patent Documents 1-3, there are reports of detecting ovarian tumors based on the expression level of microRNAs (miRNAs) in biological samples, including blood.

[0007] Specifically, Patent Document 1 describes a method for detecting ovarian cancer and predicting its prognosis using miR-191, miR-24, miR-320, miR-328, miR-625-3p, miR-483-5p, miR-92a, miR-1290, etc., in plasma.

[0008] Patent document 2 indicates that miR-135a-3 in the blood is a biomarker for gynecological cancers.

[0009] Patent Document 3 shows miR-125a-3p, miR-211-3, etc., as biomarkers for ovarian cancer using human tissue samples.

[0010] Patent Document 4 describes a method for distinguishing between endometriosis and endometriosis-derived ovarian cancer or serous ovarian cancer using miR-191-5p, miR-652-5p, miR-744-5p, miR-1246, etc., in plasma.

[0011] Non-patent document 1 lists miR-92a, miR-128, miR-191-5p, miR-296-5p, miR-320a, and miR-625-3p in the blood as circulating extracellular miRNAs involved in ovarian cancer.

[0012] Non-patent document 2 shows that analysis of miRNAs derived from serum samples of ovarian cancer patients, benign disease patients, and healthy individuals using next-generation sequencing revealed differences in the expression levels of miR-22, miR-45, and other miRNAs.

[0013] Non-patent document 3 shows that miR-23a / b, miR-92, miR-125a, miR-296-5p, miR-320, miR-422a, miR-663a, etc., are present in the vesicles of ovarian cancer patients.

[0014] Non-patent document 4 reports that the blood marker CA-125 had a sensitivity of 77.4% and a specificity of 70.8% for detecting ovarian cancer. [Prior art documents] [Patent Documents]

[0015] [Patent Document 1] U.S. Patent Application Publication No. 2016 / 0312301 [Patent Document 2] Japanese Patent Publication No. 2010-154843 [Patent Document 3] Special Publication No. 2010-538610 [Patent Document 4] International Publication No. 2013 / 148151 [Non-patent literature]

[0016] [Non-Patent Document 1] Nakamura K. et al., 2016, Molelular Cancer. Vol. 15, (1):48. [Non-Patent Document 2] Ji T. et al., 2014, Asian Pacific Journal of Cancer Prevention, Vol. 15, (4):1739. [Non-Patent Document 3] Giusti I. et al., 2013, BioMed Research International, Vol. 2013, 703048. [Non-Patent Document 4] Kim YW et al., 2012, PLoS One, Vol. 7, (9):e44960 [Overview of the project] [Problems that the invention aims to solve]

[0017] The object of the present invention is to discover a novel ovarian tumor marker and to provide a method for effectively detecting ovarian tumors using nucleic acids for detecting said marker.

[0018] It is difficult to detect ovarian tumors from subjective symptoms, and there are considered to be only two screening methods for ovarian tumors: transvaginal ultrasonography and the tumor marker CA-125 test. However, although transvaginal ultrasonography can detect tumors using ultrasound from within the vagina, the range that ultrasound can reach is limited, and there is a possibility that tumors located away from the vagina cannot be detected. In addition, CA-125 is a protein in blood that is said to be increased in patients with ovarian tumors, but it is more often increased for reasons unrelated to ovarian tumors; on the other hand, some patients with ovarian tumors do not have increased CA-125 levels, so the CA-125 test is not an effective screening test. Furthermore, as described above, according to Non-Patent Document 4, it has been reported that CA-125 has a sensitivity of 77.4% and a specificity of 70.8% for detecting ovarian cancer.

[0019] It is also known that even when transvaginal ultrasonography and the tumor marker CA-125 test are performed, these examinations do not lead to a reduction in ovarian cancer mortality.

[0020] Although there have been reports at the research stage, as described below, on discriminating ovarian tumors using the expression level of miRNA in biological samples including blood, none of these methods have been put into practical use.

[0021] Patent Document 1 discloses a method for detecting ovarian cancer and a method for predicting prognosis using miRNAs such as miR-191, miR-24, miR-320, miR-328, miR-625-3p, miR-483-5p, miR-92a, and miR-1290 in plasma. However, these miRNAs are also expressed in the control group, so they are not suitable for a method of detecting the presence or absence of ovarian cancer. In addition, the number of specimens tested is small, being only several tens of cases, so the reliability of the markers is low.

[0022] Patent Document 2 discloses that miRNAs such as miR-135a-3 in blood are useful as biomarkers for gynecological cancers. However, only differences in miRNA expression related to endometrial cancer are shown, there is no description of specific detection performance such as accuracy, sensitivity, and specificity for discriminating ovarian cancer, and thus industrial applicability is poor.

[0023] Patent Document 3 describes miRNAs such as miR-125a-3p and miR-211-3 as biomarkers for ovarian cancer using human tissue samples. However, obtaining tissue samples requires surgical tissue removal, a process that places a heavy physical burden on the patient, making it undesirable as a testing method. Furthermore, it lacks description of the detection performance, such as specific accuracy, sensitivity, and specificity for identifying ovarian cancer, and therefore has little industrial practicality.

[0024] Patent document 4 describes a method for differentiating endometriosis from endometriosis-derived ovarian cancer and serous ovarian cancer using miRNAs such as miR-191-5p, miR-652-5p, miR-744-5p, and miR-1246 in plasma. However, it does not show how to differentiate ovarian cancer from other cancers, so there is a risk of mistakenly detecting other cancers as ovarian cancer. Furthermore, the number of samples tested was small, only a few dozen cases, resulting in low reliability of the markers.

[0025] Non-patent document 1 lists miR-92a, miR-128, miR-191-5p, miR-296-5p, miR-320a, and miR-625-3p as circulating extracellular miRNAs associated with ovarian cancer. However, the detection sensitivity of ovarian epithelial cancer using the combination of miR-205 and let-7f is low at 62.4%, raising concerns about missed ovarian cancer diagnoses. Furthermore, while some studies have shown the ability to distinguish between ovarian cancer and healthy individuals using combinations of other miRNAs, patients with other cancers were not included in the research. This poses a risk of misidentifying other cancers as ovarian cancer, leading to unnecessary additional tests and delays in detecting the actual cancer, which is undesirable.

[0026] Non-patent document 2 shows that analysis of miRNAs derived from serum samples of ovarian cancer patients, benign disease patients, and healthy individuals using a next-generation sequencer revealed differences in the expression levels of miRNAs such as miR-22 and miR-45. However, it lacks any description of the detection performance, such as the specific accuracy, sensitivity, and specificity required to distinguish ovarian cancer, making it impractical for industrial use.

[0027] Non-patent document 3 shows that miRNAs such as miR-23a / b, miR-92, miR-125a, miR-296-5p, miR-320, miR-422a, and miR-663a are present in the endoplasmic reticulum of body fluids of ovarian cancer patients. However, it does not describe the specific accuracy, sensitivity, and specificity of detection performance for identifying ovarian cancer, and therefore lacks industrial practicality.

[0028] Thus, in detecting ovarian tumors, existing tumor markers have low performance, and for markers still in the research stage, the performance and detection methods have not been specifically demonstrated. Therefore, using these markers may lead to unnecessary additional tests due to misidentification of healthy individuals as ovarian tumor patients, or to missed treatment opportunities due to overlooking ovarian tumor patients. Furthermore, taking ovarian tissue to measure tumor markers is highly invasive and undesirable for patients. Therefore, there is a need for a highly accurate ovarian cancer marker that can be detected from blood, which can be collected minimally invasively, and that can correctly distinguish between ovarian tumor patients and healthy individuals. In particular, since the risk of recurrence can be dramatically reduced by early detection and treatment of ovarian cancer, and that partial resection surgery can maintain a woman's ability to have children afterward, there is a strong desire for a highly sensitive ovarian cancer marker that can detect even early-stage ovarian cancer. Moreover, it is expected that providing a simpler primary screening test for ovarian tumors will lead to an increase in the rate of participation in secondary examinations. [Means for solving the problem]

[0029] As a result of diligent research to solve the above problems, the inventors of the present invention have discovered a microRNA (miRNA) gene marker that can be used as a detection marker for ovarian tumors from blood that can be collected minimally invasively. They have found that ovarian tumors can be detected significantly, preferably specifically, by using at least one or at least two nucleic acids selected from nucleic acids for detecting this marker, such as a probe that can specifically bind to the marker and a primer that amplifies the marker, and have completed the present invention.

[0030] <Summary of the Invention> In other words, the present invention has the following features. (1) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markers,miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675-5p, miR-711 miR-6875-5p miR-3160-5p miR-1908-5p miR-6726-5p miR-1913 miR-8071 miR-3648 miR-4732-5p miR-4787-5p miR-3917 miR-619-5p miR- 1231, miR-342-5p, miR-4433a-5p, miR-6766-5p, miR-4707-5p, miR-7114-5p, miR-6872-3p, miR-6780b-5p, miR-7845-5p, miR-6798-3p, miR-665, miR -6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-6877-5p, miR-6 721-5p, miR-4656, miR-1229-5p, miR-4433a-3p, miR-4274, miR-4419b, miR-4674, miR-6893-5p, miR-6763-3p, miR-6762-5p, miR-6738-5p, miR-4513 miR-6746-5p miR-6880-5p miR-4736 miR-718 miR-6717-5p miR-7847-3p miR-760 miR-1199-5p miR-6813-5p miR-6769a-5p miR-1193 miR- 7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5p, miR-4746-3pmiR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR -208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619- 3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR -187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-679 4-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, A kit for detecting ovarian tumors, comprising at least one polynucleotide selected from miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, or a nucleic acid that can specifically bind to the complementary chain of said polynucleotide.

[0031] (2) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR- 8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-m iR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p is hsa-miR-6858-5p, miR-4690-5p is hsa-miR-4690-5p, miR-6765-5p is hsa-miR-6765-5p, miR-4710 is hsa-miR-4710, miR-6775-5p is hsa-miR-6775-5p, miR-371a-5p is hsa-miR-371a-5p, miR-6816-5p is hsa-miR-6816-5p, and miR-296-3p is hsa-m iR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, mi R-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. Yes, miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734.miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 The following are the same numbers: hsa-miR-8071, miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665.miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, and miR-4747-3p is hsa-miR-4747-3p. miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, miR-7150 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, and miR-6721-5p is hsa-miR-6721-5p. Yes, miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, miR-4419b is hsa-miR-4419b, miR-4674 is hsa-miR-4674, and miR-6 893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, miR-4736 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, and miR-6769a-5p is hsa-miR-6 769a-5p, miR-1193 is hsa-miR-1193, miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, m iR-4749-3p is hsa-miR-4749-3p, miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, and miR-6797-5p is hsa- miR-6797-5p is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, and miR-4534 is hsa-miR-4534.miR-3135b is hsa-miR-3135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, and miR-4430 is hsa-miR -4430, miR-3195 is hsa-miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p, and miR-190 8-3p is hsa-miR-1908-3p, miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, and miR-1254 is hsa- miR-1254 is hsa-miR-4727-3p is hsa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6794-5p is hsa-miR-6794-5p,miR-4687-3p is hsa-miR-4687-3p, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, and miR-42 71 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, miR-4270 is hsa-miR-4270, miR-4516 is hsa-miR-4516, miR-4651 is hsa-miR-4651, and miR-4 725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, and miR-6891-5p The kit described in (1) is such that is hsa-miR-6891-5p, miR-7108-5p is hsa-miR-7108-5p, miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0032] (3) The nucleic acid is a polynucleotide as shown in any of (a) to (e) below: (a) A polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (b) Polynucleotides containing a base sequence represented by any of sequence numbers 1-247, 251 and 268, (c) A polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence complementary to the nucleotide sequence in said nucleotide sequence where u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (d) A polynucleotide containing a nucleotide sequence that is complementary to any of the nucleotide sequences represented by SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence in which u is t, and (e) A polynucleotide that hybridizes with any of the polynucleotides in (a) to (d) above under stringent conditions, The kit according to (1) or (2), which is a polynucleotide selected from the group consisting of the following.

[0033] (4) The above kit is for another ovarian tumor marker, miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, mi A kit according to any one of (1) to (3), further comprising at least one polynucleotide selected from R-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, miR-22-3p, or a nucleic acid that can specifically bind to the complementary chain of said polynucleotide.

[0034] (5) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hsa -miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, miR-211-3p is hsa-miR-211-3p, miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-48 The kit described in (4) is 3-5p, where miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p.

[0035] (6) The above nucleic acid is a polynucleotide as shown in any of (f) to (j) below: (f) A polynucleotide consisting of a base sequence represented by any of sequence numbers 248-250, 252-267, and 269-275, or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases. (g) Polynucleotides containing a base sequence represented by any of the sequence numbers 248-250, 252-267, and 269-275, (h) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 248-250, 252-267, and 269-275, or a nucleotide sequence complementary to the nucleotide sequence in said sequence where u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (i) A polynucleotide containing a nucleotide sequence that is complementary to any of the nucleotide sequences represented by SEQ ID NOs. 248-250, 252-267, and 269-275, or a nucleotide sequence in which u is t, and (j) A polynucleotide that hybridizes with any of the polynucleotides in (f) to (i) above under stringent conditions. The kit according to (4) or (5), which is a polynucleotide selected from the group consisting of the following.

[0036] (7) The kit according to any one of (1) to (6), wherein the kit comprises at least two polynucleotides selected from all the ovarian tumor markers described in (1) or (2), or at least two nucleic acids that can specifically bind to each of the complementary strands of the polynucleotides.

[0037] (8) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markers,miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675-5p, miR-711 miR-6875-5p miR-3160-5p miR-1908-5p miR-6726-5p miR-1913 miR-8071 miR-3648 miR-4732-5p miR-4787-5p miR-3917 miR-619-5p miR- 1231, miR-342-5p, miR-4433a-5p, miR-6766-5p, miR-4707-5p, miR-7114-5p, miR-6872-3p, miR-6780b-5p, miR-7845-5p, miR-6798-3p, miR-665, miR -6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-6877-5p, miR-6 721-5p, miR-4656, miR-1229-5p, miR-4433a-3p, miR-4274, miR-4419b, miR-4674, miR-6893-5p, miR-6763-3p, miR-6762-5p, miR-6738-5p, miR-4513 miR-6746-5p miR-6880-5p miR-4736 miR-718 miR-6717-5p miR-7847-3p miR-760 miR-1199-5p miR-6813-5p miR-6769a-5p miR-1193 miR- 7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5p, miR-4746-3pmiR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR -208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619- 3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR -187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-679 4-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, A device for detecting ovarian tumors, comprising at least one polynucleotide selected from miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, or a nucleic acid that can specifically bind to the complementary chain of said polynucleotide.

[0038] (9) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR- 8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-m iR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p is hsa-miR-6858-5p, miR-4690-5p is hsa-miR-4690-5p, miR-6765-5p is hsa-miR-6765-5p, miR-4710 is hsa-miR-4710, miR-6775-5p is hsa-miR-6775-5p, miR-371a-5p is hsa-miR-371a-5p, miR-6816-5p is hsa-miR-6816-5p, and miR-296-3p is hsa-m iR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, mi R-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. Yes, miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734.miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 The following are the same numbers: hsa-miR-8071, miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665.miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, and miR-4747-3p is hsa-miR-4747-3p. miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, miR-7150 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, and miR-6721-5p is hsa-miR-6721-5p. Yes, miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, miR-4419b is hsa-miR-4419b, miR-4674 is hsa-miR-4674, and miR-6 893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, miR-4736 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, and miR-6769a-5p is hsa-miR-67 69a-5p, miR-1193 is hsa-miR-1193, miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, miR- 4749-3p is hsa-miR-4749-3p, miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, and miR-6797-5p is hs a-miR-6797-5p is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, and miR-4534 is hsa-miR-4 534 is, miR-3135b is hsa-miR-3135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, and miR-4430 is hsa-miR-4430, miR-3195 is hsa-miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p,miR-1908-3p is hsa-miR-1908-3p, miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, and miR-125 4 is hsa-miR-1254, miR-4727-3p is hsa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, and miR-6794-5p is hsa-miR-6794-5 p is, miR-4687-3p is hsa-miR-4687-3p, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, miR-4271 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, and miR-4270 is h sa-miR-4270 is hsa-miR-4516, miR-4651 is hsa-miR-4651, miR-4725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, miR-6891-5p is hsa-miR-6891-5p,The device described in (8), where miR-7108-5p is hsa-miR-7108-5p, miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0039] (10) The nucleic acid is a polynucleotide as shown in any of (a) to (e) below: (a) A polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (b) Polynucleotides containing a base sequence represented by any of sequence numbers 1-247, 251 and 268, (c) A polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence complementary to the nucleotide sequence in said nucleotide sequence where u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (d) A polynucleotide containing a nucleotide sequence that is complementary to any of the nucleotide sequences represented by SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence in which u is t, and (e) A polynucleotide that hybridizes with any of the polynucleotides in (a) to (d) above under stringent conditions, The device according to (8) or (9), wherein the polynucleotide is selected from the group consisting of the following.

[0040] (11) The above device is a different ovarian tumor marker, miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, m The device according to any one of (8) to (10), further comprising at least one polynucleotide selected from iR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, and miR-22-3p, or a nucleic acid that can specifically bind to the complementary chain of said polynucleotide.

[0041] (12) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hs a-miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, and miR-211-3p is hsa-miR-211-3p. miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-483 The device described in (11), wherein miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p.

[0042] (13) The above nucleic acid is a polynucleotide as shown in any of (f) to (j) below: (f) A polynucleotide consisting of a base sequence represented by any of sequence numbers 248-250, 252-267, and 269-275, or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases. (g) Polynucleotides containing a base sequence represented by any of the sequence numbers 248-250, 252-267, and 269-275, (h) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 248-250, 252-267, and 269-275, or a nucleotide sequence complementary to the nucleotide sequence in said sequence where u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (i) A polynucleotide containing a nucleotide sequence that is complementary to any of the nucleotide sequences represented by SEQ ID NOs. 248-250, 252-267, and 269-275, or a nucleotide sequence in which u is t, and (j) A polynucleotide that hybridizes with any of the polynucleotides in (f) to (i) above under stringent conditions. The device according to (11) or (12), wherein the polynucleotide is selected from the group consisting of the following.

[0043] (14) The device described in any of (8) to (13), wherein the above device is a device for measurement by hybridization technology.

[0044] (15) The device according to (14), wherein the hybridization technology described above is nucleic acid array technology.

[0045] (16) The device according to any one of (8) to (15), wherein the device comprises at least two polynucleotides selected from all ovarian tumor markers described in (8) or (9), or at least two nucleic acids that can specifically bind to each of the complementary strands of said polynucleotides.

[0046] (17) R-4532、miR-6802-5p、miR-6784-5p、miR-3940-5p、miR-1307-3p、miR-807 3、miR-3184-5p、miR-1233-5p、miR-6088、miR-5195-3p、miR-320b、miR-46 49-5p、miR-6800-5p、miR-1343-3p、miR-4730、miR-6885-5p、miR-5100、mi R-1203、miR-6756-5p、miR-373-5p、miR-1268a、miR-1260b、miR-4258、miR -4697-5p、miR-1469、miR-4515、miR-6861-5p、miR-6821-5p、miR-575、miR -6805-5p、miR-4758-5p、miR-3663-3p、miR-4530、miR-6798-5p、miR-6781 -5p、miR-885-3p、miR-1273g-3p、miR-4787-3p、miR-4454、miR-4706、miR-1 249-3p、miR-887-3p、miR-6786-5p、miR-1238-5p、miR-6749-5p、miR-6729 -5p、miR-6825-5p、miR-663b、miR-6858-5p、miR-4690-5p、miR-6765-5p、m iR-4710、miR-6775-5p、miR-371a-5p、miR-6816-5p、miR-296-3p、miR-797 7、miR-8069、miR-6515-3p、miR-4687-5p、miR-1343-5p、miR-7110-5p、miR- 4525、miR-3158-5p、miR-6787-5p、miR-614、miR-4689、miR-1185-2-3p、mi R-1268b、miR-1228-3p、miR-1185-1-3p、miR-940、miR-939-5p、miR-6757- 5p、miR-1275、miR-5001-5p、miR-6826-5p、miR-6765-3p、miR-3679-3p、mi R-4718、miR-4286、miR-8059、miR-4447、miR-4448、miR-658、miR-6766-3p、miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6 132, miR-4734, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675 -5p、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、miR- 619-5p, miR-1231, miR-342-5p, miR-4433a-5p, miR-6766-5p, miR-4707-5p, miR-7114-5p, miR-6872-3p, miR-6780b-5p, miR-7845-5p, miR-6798-3p miR-665, miR-6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-68 77-5p, miR-6721-5p, miR-4656, miR-1229-5p, miR-4433a-3p, miR-4274, miR-4419b, miR-4674, miR-6893-5p, miR-6763-3p, miR-6762-5p, miR-6738 -5p, miR-4513, miR-6746-5p, miR-6880-5p, miR-4736, miR-718, miR-6717-5p, miR-7847-3p, miR-760, miR-1199-5p, miR-6813-5p, miR-6769a-5p, m iR-1193, miR-7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5pmiR-4746-3p, miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-51 96-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR -3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5 p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-451 6. A method for detecting ovarian tumors, comprising measuring the expression level of at least one polynucleotide selected from miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, and using the measured expression level to evaluate in vitro whether a subject has or does not have an ovarian tumor.

[0047] (18) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markers,miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675-5p, miR-711 miR-6875-5p miR-3160-5p miR-1908-5p miR-6726-5p miR-1913 miR-8071 miR-3648 miR-4732-5p miR-4787-5p miR-3917 miR-619-5p miR- 1231, miR-342-5p, miR-4433a-5p, miR-6766-5p, miR-4707-5p, miR-7114-5p, miR-6872-3p, miR-6780b-5p, miR-7845-5p, miR-6798-3p, miR-665, miR -6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-6877-5p, miR-6 721-5p, miR-4656, miR-1229-5p, miR-4433a-3p, miR-4274, miR-4419b, miR-4674, miR-6893-5p, miR-6763-3p, miR-6762-5p, miR-6738-5p, miR-4513 miR-6746-5p miR-6880-5p miR-4736 miR-718 miR-6717-5p miR-7847-3p miR-760 miR-1199-5p miR-6813-5p miR-6769a-5p miR-1193 miR- 7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5p, miR-4746-3pmiR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842- 5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, m iR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, m iR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, m iR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-42 57, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109 A method for detecting ovarian tumors, comprising measuring the expression level of a target nucleic acid in a subject's sample using a kit according to any one of (1) to (7) or a device according to any one of (8) to (16), which comprises at least one or at least two polynucleotides selected from -5p, miR-642b-3p, and miR-642a-3p, or nucleic acids that can specifically bind to each of the complementary strands of said polynucleotide; and evaluating in vitro whether the subject has or does not have an ovarian tumor using the measured expression level and the similarly measured control expression level of a healthy individual.

[0048] (19) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markers,miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675-5p, miR-711 miR-6875-5p miR-3160-5p miR-1908-5p miR-6726-5p miR-1913 miR-8071 miR-3648 miR-4732-5p miR-4787-5p miR-3917 miR-619-5p miR- 1231, miR-342-5p, miR-4433a-5p, miR-6766-5p, miR-4707-5p, miR-7114-5p, miR-6872-3p, miR-6780b-5p, miR-7845-5p, miR-6798-3p, miR-665, miR -6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-6877-5p, miR-6 721-5p, miR-4656, miR-1229-5p, miR-4433a-3p, miR-4274, miR-4419b, miR-4674, miR-6893-5p, miR-6763-3p, miR-6762-5p, miR-6738-5p, miR-4513 miR-6746-5p miR-6880-5p miR-4736 miR-718 miR-6717-5p miR-7847-3p miR-760 miR-1199-5p miR-6813-5p miR-6769a-5p miR-1193 miR- 7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5p, miR-4746-3pmiR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, mi R-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, mi R-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR- 6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777- 5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR- Select from 4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, miR-642a-3p. Using a kit according to any one of (1) to (7) or a device according to any one of (8) to (16), comprising at least one or at least two selected polynucleotides, or nucleic acids that can specifically bind to each of the complementary strands of said polynucleotide, the expression level of the target gene in the subject's sample is measured, and the gene expression levels of a sample from a subject known to have an ovarian tumor and the gene expression levels of a sample from a subject without an ovarian tumor are used as training samples to create a discriminant formula that can distinguish between the presence or absence of an ovarian tumor.A method for detecting ovarian tumors, comprising substituting the expression level of a target gene in a sample derived from the above-mentioned subject, thereby evaluating the presence or absence of ovarian tumors in vitro.

[0049] (20) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR -8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-m iR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p is hsa-miR-6858-5p, miR-4690-5p is hsa-miR-4690-5p, miR-6765-5p is hsa-miR-6765-5p, miR-4710 is hsa-miR-4710, miR-6775-5p is hsa-miR-6775-5p, miR-371a-5p is hsa-miR-371a-5p, miR-6816-5p is hsa-miR-6816-5p, and miR-296-3p is hsa-m iR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, mi R-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. Yes, miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734.miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 The following are the same numbers: hsa-miR-8071, miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665.miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, miR-4747-3p is hsa-miR-4747-3p, miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, and miR-715 0 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, miR-6721-5p is hsa-miR-6721-5p, miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, and miR-4419b is hsa-miR-4419b. miR-4674 is hsa-miR-4674, miR-6893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, and miR-473 6 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, miR-6769a-5p is hsa-miR-6769a-5p, miR-1193 is hsa-miR-1193,miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, miR-4749-3p is hsa-miR-4749-, It is 3p, and miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, miR-6797-5p is hsa-miR-6797-5p, and miR-147 0 is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, miR-4534 is hsa-miR-4534, and miR-3135b is hsa-miR-3 135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, miR-4430 is hsa-miR-4430, and miR-3195 is hsa -miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p, miR-1908-3p is hsa-miR-1908-3p,miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, miR-1254 is hsa-miR-1254, and miR-4727-3p is h sa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6794-5p is hsa-miR-6794-5p, and miR-4687-3p is hsa-miR-4687-3 p is, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, miR-4271 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, miR-4270 is hsa-miR-4270, and miR-4516 is hsa-miR -4516, miR-4651 is hsa-miR-4651, miR-4725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, miR-6891-5p is hsa-miR-6891-5p, miR-7108-5p is hsa-miR-7108-5p,The method according to any of (17) to (19), wherein miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0050] (21) The nucleic acid is a polynucleotide as shown in any of (a) to (e) below: (a) A polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1-247, 251, and 268, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (b) Polynucleotides containing a base sequence represented by any of sequence numbers 1-247, 251 and 268, (c) A polynucleotide consisting of a nucleotide sequence complementary to any of the nucleotide sequences represented by Sequence IDs 1-247, 251, and 268, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (d) A polynucleotide containing a nucleotide sequence complementary to any of the nucleotide sequences represented by sequence numbers 1-247, 251, and 268, or a nucleotide sequence in which u is t, and (e) A polynucleotide that hybridizes with any of the polynucleotides in (a) to (d) above under stringent conditions, The method according to any one of (17) to (19), wherein the polynucleotide is selected from the group consisting of the following.

[0051] (22) The above kit or device is not a separate ovarian tumor marker, miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3 The method according to any one of (17) to (21), further comprising at least one polynucleotide selected from p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, miR-22-3p, or a nucleic acid that can specifically bind to the complementary chain of said polynucleotide.

[0052] (23) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hs a-miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, and miR-211-3p is hsa-miR-211-3p. miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-4 The method according to (22), wherein 83-5p is, miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p.

[0053] (24) The above nucleic acid is a polynucleotide shown in any of (f) to (j) below: (f) A polynucleotide comprising a nucleotide sequence represented by any of sequence numbers 248-250, 252-267, and 269-275, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (g) Polynucleotides containing a base sequence represented by any of the sequence numbers 248-250, 252-267, and 269-275, (h) A polynucleotide consisting of a nucleotide sequence complementary to any of the nucleotide sequences represented by sequence numbers 248-250, 252-267, and 269-275, or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides. (i) A polynucleotide containing a nucleotide sequence complementary to any of the nucleotide sequences represented by sequence numbers 248-250, 252-267, and 269-275, or a nucleotide sequence in which u is t, and (j) A polynucleotide that hybridizes with any of the polynucleotides in (f) to (i) above under stringent conditions. The method according to (22) or (23), wherein the polynucleotide is selected from the group consisting of the following.

[0054] (25) The method according to any of (17) to (24), wherein the subject is a human.

[0055] (26) The method according to any one of (17) to (25), wherein the above specimen is blood, serum, or plasma.

[0056] <Definition of Terms> The terms used herein have the following definitions: Abbreviations such as nucleotide, polynucleotide, DNA, and RNA shall be used in accordance with the "Guidelines for the Preparation of Specifications Including Base Sequences or Amino Acid Sequences" (compiled by the Japan Patent Office) and common practice in the art.

[0057] In this specification, "polynucleotide" is used for nucleic acids that include RNA, DNA, and RNA / DNA (chimeras). DNA includes cDNA, genomic DNA, and synthetic DNA. RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to DNA and RNA artificially produced, for example, using an automated nucleic acid synthesizer, based on a predetermined base sequence (which may be either a natural or non-natural sequence). In this specification, "non-natural sequence" is intended to be used in a broad sense and includes sequences that differ from the natural sequence, such as sequences containing one or more nucleotide substitutions, deletions, insertions, and / or additions (i.e., mutant sequences), sequences containing one or more modified nucleotides (i.e., modified sequences), etc. Furthermore, in this specification, polynucleotide is used interchangeably with nucleic acid.

[0058] In this specification, "fragment" refers to a polynucleotide having a continuous base sequence of a portion of a polynucleotide, and it is desirable that the fragment has a length of 15 bases or more, preferably 17 bases or more, and more preferably 19 bases or more.

[0059] In this specification, “gene” is used to include not only RNA and double-stranded DNA, but also each single-stranded DNA such as the positive (or sense) strand or complementary (or antisense) strand that constitutes them, and is not particularly limited by its length. Accordingly, unless otherwise specified, “gene” in this specification includes any of the following: double-stranded DNA including human genomic DNA, single-stranded DNA (positive strand), single-stranded DNA (complementary strand) having a sequence complementary to the positive strand, cDNA, microRNA (miRNA), and fragments thereof, the human genome, and their transcripts. Furthermore, “gene” includes not only “genes” represented by a specific base sequence (or sequence number), but also “nucleic acids” that encode RNAs with biological function equivalent to the RNA encoded by them, such as homologs (i.e., orthologs), variants such as genetic polymorphisms, and derivatives. Specifically, "nucleic acids" encoding such congeners, mutants, or derivatives include "nucleic acids" having a base sequence that hybridizes with a complementary sequence of any of the base sequences represented by sequence numbers 1 to 842, or a base sequence in which u is replaced by t, under the stringent conditions described later. Note that "genes" are not limited to functional regions and may include, for example, expression regulatory regions, coding regions, exons, or introns. Furthermore, "genes" may be contained within cells, released extracellularly and existing independently, or encapsulated in vesicles called exosomes.

[0060] In this specification, "exosome" refers to a lipid bilayer-encased vesicle secreted by a cell. Exosomes originate from multivesicular endosomes and may contain biomolecules such as RNA, DNA, and proteins when released into the extracellular environment. Exosomes are known to be found in bodily fluids such as blood, serum, plasma, and lymph.

[0061] In this specification, "transcript" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a site called the promoter located upstream of the gene, and RNA is synthesized by attaching ribonucleotides to the 3' end in a manner complementary to the DNA base sequence. This RNA contains not only the gene itself, but also the entire sequence from the transcription start site to the end of the poly(A) sequence, including the expression regulatory region, coding region, exons, or introns.

[0062] Furthermore, in this specification, unless otherwise specified, "microRNA (miRNA)" refers to a 15-25 nucleotide non-coding RNA that is transcribed as a hairpin-like RNA precursor, cleaved by a dsRNA-cleaving enzyme with RNase III cleavage activity, incorporated into a protein complex called RISC, and involved in the repression of mRNA translation. In addition, the term "miRNA" as used herein includes not only "miRNA" represented by a specific nucleotide sequence (or sequence number), but also "miRNA" that includes precursors (pre-miRNA, pri-miRNA) of the said "miRNA" and has the same biological function as the miRNA encoded by these precursors, such as homologs (i.e., orthologs), variants such as gene polymorphisms, and derivatives. Examples of "miRNAs" encoding such precursors, congeners, mutants, or derivatives include those that can be identified by miRBase release 21 (http: / / www.mirbase.org / ) and have a nucleotide sequence that hybridizes with the complementary sequence of any specific nucleotide sequence represented by SEQ ID NOs. 1 to 842 under the stringent conditions described later. Furthermore, the "miRNAs" used herein may also be gene products of miR genes, and such gene products include mature miRNAs (e.g., non-coding RNAs of 15-25 nucleotides or 19-25 nucleotides involved in the translational repression of mRNA as described above) or miRNA precursors (e.g., pre-miRNAs or pri-miRNAs as described above).

[0063] In this specification, "probe" includes polynucleotides and / or complementary polynucleotides used to specifically detect RNA or polynucleotides derived therefrom that are produced by gene expression.

[0064] In this specification, "primer" includes a sequence of polynucleotides and / or complementary polynucleotides that specifically recognize and amplify RNA or polynucleotides derived therefrom produced by gene expression.

[0065] Here, a complementary polynucleotide (complementary chain, reverse chain) refers to a polynucleotide that is nucleotide-complementary to the full-length sequence of a polynucleotide consisting of a base sequence defined by any of sequence numbers 1 to 842, or a base sequence in which u is replaced by t, or a partial sequence thereof (for convenience, this will be called the forward chain), based on base pair relationships such as A:T(U) and G:C. However, such a complementary chain is not limited to forming a perfectly complementary sequence with the base sequence of the target forward chain; it may also have a complementary relationship to the target forward chain that allows for hybridization under stringent conditions.

[0066] In this specification, "stringent conditions" refer to conditions under which a nucleic acid probe hybridizes to its target sequence to a detectably greater extent than to other sequences (e.g., a measurement of the mean of background measurements + standard error of background measurements × 2 or more). Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization takes place. By controlling the stringency of hybridization and / or washing conditions, target sequences that are 100% complementary to the nucleic acid probe can be identified. Specific examples of "stringent conditions" will be described later. In this specification, "Tm value" refers to the temperature at which the double-stranded portion of a polynucleotide denatures into a single-stranded portion, and in which the double-stranded and single-stranded portions exist in a 1:1 ratio.

[0067] In this specification, "mutant" means, in the case of nucleic acids, a naturally occurring mutant resulting from polymorphism, mutation, etc., or a mutant containing the deletion, substitution, addition, or insertion of 1, 2, 3 or more (e.g., 1 to several) bases in a nucleotide sequence represented by the sequence number, or a nucleotide sequence in which u is t, or a subsequence thereof, or a mutant containing the deletion, substitution, addition, or insertion of 1 or more bases in a premature miRNA of any sequence of sequence numbers 1 to 275, or a nucleotide sequence in which u is t, or a subsequence thereof, or a mutant showing approximately 90% or more, approximately 95% or more, approximately 97% or more, approximately 98% or more, or approximately 99% or more % identity with each of the above nucleotide sequences or subsequences thereof, or a nucleic acid that hybridizes with a polynucleotide or oligonucleotide containing the above nucleotide sequence or subsequences thereof under the stringent conditions defined above.

[0068] In this specification, “a number of” means approximately 10, 9, 8, 7, 6, 5, 4, 3, or 2 integers.

[0069] In this specification, mutants can be produced using well-known techniques such as site-directed mutagenesis and mutation induction methods using PCR.

[0070] In this specification, "% identity" can be determined with or without introducing gaps using protein or gene search systems such as BLAST (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) or FASTA (http: / / www.genome.jp / tools / fasta / ) (Zheng Zhang et al., 2000, J.Comput.Biol., vol. 7, pp. 203-214; Altschul, SF et al., 1990, Journal of Molecular Biology, vol. 215, pp. 403-410; Pearson, WR et al., 1988, Proc.Natl.Acad.Sci.USA, vol. 85, pp. 2444-2448).

[0071] In this specification, "derivative" means modified nucleic acids, non-limited derivatives labeled with, for example, fluorophores, derivatives containing modified nucleotides (e.g., nucleotides containing halogens, alkyl groups such as methyl, alkoxy groups such as methoxy, thio, carboxymethyl, etc., and derivatives containing nucleotides that have undergone base reconfiguration, double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, etc.), PNA (peptide nucleic acid; Nielsen, PE et al., 1991, Science, Vol. 254, pp. 1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, pp. 5401-5404), etc.

[0072] In this specification, polynucleotides selected from the above-mentioned ovarian tumor marker miRNA, or "nucleic acids" that can specifically bind to the complementary strand of said polynucleotide, or "nucleic acids" that can detect said polynucleotide are synthesized or prepared nucleic acids, including, for example, "nucleic acid probes" or "primers," and are used directly or indirectly to detect the presence or absence of ovarian tumors in a subject, or to diagnose the presence or absence of ovarian tumors, the extent of the disease, the presence or extent of improvement of ovarian tumors, the sensitivity of ovarian tumors to treatment, or to screen for candidate substances useful for the prevention, improvement, or treatment of ovarian tumors. These include nucleotides, oligonucleotides, and polynucleotides that can specifically recognize and bind to transcripts represented by any of SEQ ID NOs: 1 to 842 or their cDNA synthetic nucleic acids in vivo, particularly in body fluids such as blood and urine, in relation to the presence of ovarian tumors. Based on the above properties, these nucleotides, oligonucleotides, and polynucleotides can be effectively used as probes for detecting the above-mentioned genes expressed in vivo, in tissues, or within cells, and as primers for amplifying the above-mentioned genes expressed in vivo.

[0073] As used herein, the term “detection” may be replaced by the terms “inspection,” “measurement,” “detection,” or “assessment support.” Furthermore, as used herein, the term “assessment” includes supporting a diagnosis or assessment based on inspection or measurement results.

[0074] As used herein, "subject" refers to mammals such as humans, primates including chimpanzees, pet animals such as dogs and cats, domesticated animals such as cattle, horses, sheep, and goats, rodents such as mice and rats, and animals kept in zoos. The preferred subject is human. In this specification, "subject" may sometimes be referred to as "test subject." Similarly, "healthy person" also refers to such mammals that are not suffering from the cancer being detected, or to a subject. The preferred healthy person is human.

[0075] As used herein, "ovarian cancer" refers to a malignant tumor that develops in the ovary, and includes, for example, epithelial ovarian cancer that originates from the mucosal epithelium and germ cell stromal ovarian cancer.

[0076] As used herein, “benign ovarian tumor” refers to a benign tumor that occurs in the ovary, including, for example, mucinous cystic adenoma, serous cystadenoma, mature teratoma, and fibroma.

[0077] As used herein, the term "ovarian tumor" encompasses both "ovarian cancer" and "benign ovarian tumor" as defined above.

[0078] As used herein, "P" or "P-value" refers to the probability in a statistical test that a statistic more extreme than the statistic actually calculated from the data under the null hypothesis is observed. Therefore, a smaller "P" or "P-value" indicates a statistically significant difference between the comparison groups.

[0079] In this specification, "sensitivity" refers to the value of (number of true positives) / (number of true positives + number of false negatives). Higher sensitivity allows for the early detection of ovarian cancer, leading to complete resection of the cancerous area and a reduction in the recurrence rate.

[0080] In this specification, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). High specificity prevents unnecessary additional tests due to misidentification of healthy individuals as ovarian cancer patients, leading to reduced burden on patients and lower medical costs.

[0081] In this specification, "precision" refers to the value of (number of true positives + number of true negatives) / (total number of cases). Precision indicates the proportion of all samples for which the classification result was correct, and is the primary indicator for evaluating detection performance.

[0082] In this specification, the term "specimen" subject to determination, detection, or diagnosis refers to tissues and biomaterials in which the expression of the gene of the present invention changes in accordance with the development, progression, and therapeutic effects against ovarian cancer. Specifically, this refers to ovarian tissue and fallopian tubes, lymph nodes and surrounding organs, organs suspected of metastasis, skin, and bodily fluids such as blood, urine, saliva, sweat, and tissue exudate, as well as serum and plasma prepared from blood, stool, hair, etc. Furthermore, it refers to biological samples extracted from these, specifically genes such as RNA and miRNA.

[0083] As used herein, the terms "hsa-miR-4675 gene" or "hsa-miR-4675" include the hsa-miR-4675 gene (miRBase Accession No. MIMAT0019757) described in Sequence ID No. 1, as well as other species homologs or orthologs. The hsa-miR-4675 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4675" is known to have a hairpin-like structure as its precursor, "hsa-mir-4675" (miRBase Accession No. MI0017306, Sequence ID No. 276).

[0084] As used herein, the terms "hsa-miR-4783-3p gene" or "hsa-miR-4783-3p" include the hsa-miR-4783-3p gene (miRBase Accession No. MIMAT0019947) described in Sequence ID No. 2, as well as other species homologs or orthologs. The hsa-miR-4783-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4783-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4783" (miRBase Accession No. MI0017428, Sequence ID No. 277).

[0085] As used herein, the terms "hsa-miR-1228-5p gene" or "hsa-miR-1228-5p" include the hsa-miR-1228-5p gene (miRBase Accession No. MIMAT0005582) described in Sequence ID No. 3, as well as other species homologs or orthologs. The hsa-miR-1228-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1228" (miRBase Accession No. MI0006318, Sequence ID No. 278), which has a hairpin-like structure, is known as a precursor of "hsa-miR-1228-5p".

[0086] As used herein, the terms "hsa-miR-4532 gene" or "hsa-miR-4532" include the hsa-miR-4532 gene (miRBase Accession No. MIMAT0019071) described in Sequence ID No. 4, as well as other species homologs or orthologs. The hsa-miR-4532 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4532" is known to have a hairpin-like structure as its precursor, "hsa-mir-4532" (miRBase Accession No. MI0016899, Sequence ID No. 279).

[0087] As used herein, the terms "hsa-miR-6802-5p gene" or "hsa-miR-6802-5p" include the hsa-miR-6802-5p gene (miRBase Accession No. MIMAT0027504) described in Sequence ID No. 5, as well as other species homologs or orthologs. The hsa-miR-6802-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6802-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6802" (miRBase Accession No. MI0022647, Sequence ID No. 280).

[0088] As used herein, the terms "hsa-miR-6784-5p gene" or "hsa-miR-6784-5p" include the hsa-miR-6784-5p gene (miRBase Accession No. MIMAT0027468) described in Sequence ID No. 6, as well as other species homologs or orthologs. The hsa-miR-6784-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6784-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6784" (miRBase Accession No. MI0022629, Sequence ID No. 281).

[0089] As used herein, the terms "hsa-miR-3940-5p gene" or "hsa-miR-3940-5p" include the hsa-miR-3940-5p gene (miRBase Accession No. MIMAT0019229) described in Sequence ID No. 7, as well as other species homologs or orthologs. The hsa-miR-3940-5p gene can be obtained by the method described by Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3940-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3940" (miRBase Accession No. MI0016597, Sequence ID No. 282). As used herein, the terms "hsa-miR-1307-3p gene" or "hsa-miR-1307-3p" include the hsa-miR-1307-3p gene (miRBase Accession No. MIMAT0005951) described in Sequence ID No. 8, as well as other species homologs or orthologs. The hsa-miR-1307-3p gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1307-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1307" (miRBase Accession No. MI0006444, Sequence ID No. 283).

[0090] As used herein, the terms "hsa-miR-8073 gene" or "hsa-miR-8073" include the hsa-miR-8073 gene (miRBase Accession No. MIMAT0031000) described in Sequence ID No. 9, as well as other species homologs or orthologs. The hsa-miR-8073 gene can be obtained by the method described by Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8073" is known to have a hairpin-like structure as its precursor, "hsa-mir-8073" (miRBase Accession No. MI0025909, Sequence ID No. 284).

[0091] As used herein, the terms "hsa-miR-3184-5p gene" or "hsa-miR-3184-5p" include the hsa-miR-3184-5p gene (miRBase Accession No. MIMAT0015064) described in Sequence ID No. 10, as well as other species homologs or orthologs. The hsa-miR-3184-5p gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3184-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3184" (miRBase Accession No. MI0014226, Sequence ID No. 285).

[0092] As used herein, the terms "hsa-miR-1233-5p gene" or "hsa-miR-1233-5p" include the hsa-miR-1233-5p gene (miRBase Accession No. MIMAT0022943) described in Sequence ID No. 11, as well as other species homologs or orthologs. The hsa-miR-1233-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1233-5p" is known to have hairpin-like precursors, "hsa-mir-1233-1, hsa-mir-1233-2" (miRBase Accession No. MI0006323, MI0015973, Sequence ID No. 286, 287).

[0093] As used herein, the terms "hsa-miR-6088 gene" or "hsa-miR-6088" include the hsa-miR-6088 gene described in Sequence ID No. 12 (miRBase Accession No. MIMAT0023713) and other species homologs or orthologs. The hsa-miR-6088 gene can be obtained by the method described by Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. In addition, "hsa-miR-6088" is known to have a hairpin-like structure as its precursor, "hsa-mir-6088" (miRBase Accession No. MI0020365, Sequence ID No. 288).

[0094] As used herein, the terms "hsa-miR-5195-3p gene" or "hsa-miR-5195-3p" include the hsa-miR-5195-3p gene (miRBase Accession No. MIMAT0021127) described in Sequence ID No. 13, as well as other species homologs or orthologs. The hsa-miR-5195-3p gene can be obtained by the method described by Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. In addition, "hsa-miR-5195-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-5195" (miRBase Accession No. MI0018174, Sequence ID No. 289).

[0095] As used herein, the terms "hsa-miR-320b gene" or "hsa-miR-320b" include the hsa-miR-320b gene (miRBase Accession No. MIMAT0005792) described in Sequence ID No. 14, as well as other species homologs or orthologs. The hsa-miR-320b gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-320b" is known to have hairpin-like structures as its precursors, "hsa-mir-320b-1, hsa-mir-320b-2" (miRBase Accession No. MI0003776, MI0003839, Sequence ID No. 290, 291).

[0096] As used herein, the terms "hsa-miR-4649-5p gene" or "hsa-miR-4649-5p" include the hsa-miR-4649-5p gene (miRBase Accession No. MIMAT0019711) described in Sequence ID No. 15, as well as other species homologs or orthologs. The hsa-miR-4649-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4649-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4649" (miRBase Accession No. MI0017276, Sequence ID No. 292).

[0097] As used herein, the terms "hsa-miR-6800-5p gene" or "hsa-miR-6800-5p" include the hsa-miR-6800-5p gene (miRBase Accession No. MIMAT0027500) described in Sequence ID No. 16, as well as other species homologs or orthologs. The hsa-miR-6800-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6800-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6800" (miRBase Accession No. MI0022645, Sequence ID No. 293).

[0098] As used herein, the terms "hsa-miR-1343-3p gene" or "hsa-miR-1343-3p" include the hsa-miR-1343-3p gene (miRBase Accession No. MIMAT0019776) described in Sequence ID No. 17, as well as other species homologs or orthologs. The hsa-miR-1343-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-1343-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1343" (miRBase Accession No. MI0017320, Sequence ID No. 294).

[0099] As used herein, the terms "hsa-miR-4730 gene" or "hsa-miR-4730" include the hsa-miR-4730 gene (miRBase Accession No. MIMAT0019852) described in Sequence ID No. 18, as well as other species homologs or orthologs. The hsa-miR-4730 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4730" is known to have a hairpin-like structure as its precursor, "hsa-mir-4730" (miRBase Accession No. MI0017367, Sequence ID No. 295).

[0100] As used herein, the terms "hsa-miR-6885-5p gene" or "hsa-miR-6885-5p" include the hsa-miR-6885-5p gene (miRBase Accession No. MIMAT0027670) described in Sequence ID No. 19, as well as other species homologs or orthologs. The hsa-miR-6885-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6885-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6885" (miRBase Accession No. MI0022732, Sequence ID No. 296).

[0101] As used herein, the terms "hsa-miR-5100 gene" or "hsa-miR-5100" include the hsa-miR-5100 gene (miRBase Accession No. MIMAT0022259) described in Sequence ID No. 20, as well as other species homologs or orthologs. The hsa-miR-5100 gene can be obtained by the method described by Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. In addition, "hsa-miR-5100" is known to have a hairpin-like structure as its precursor, "hsa-mir-5100" (miRBase Accession No. MI0019116, Sequence ID No. 297).

[0102] As used herein, the terms "hsa-miR-1203 gene" or "hsa-miR-1203" include the hsa-miR-1203 gene (miRBase Accession No. MIMAT0005866) described in Sequence ID No. 21, as well as other species homologs or orthologs. The hsa-miR-1203 gene can be obtained by the method described by Marton S et al., 2008, Leukemia, Vol. 22, pp. 330-338. In addition, "hsa-miR-1203" is known to have a hairpin-like structure as its precursor, "hsa-mir-1203" (miRBase Accession No. MI0006335, Sequence ID No. 298).

[0103] The terms "hsa-miR-6756-5p gene" or "hsa-miR-6756-5p" as used herein include the hsa-miR-6756-5p gene (miRBase Accession No. MIMAT0027412) described in Sequence ID No. 22, as well as other species homologs or orthologs. The hsa-miR-6756-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6756-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6756" (miRBase Accession No. MI0022601, Sequence ID No. 299).

[0104] As used herein, the terms "hsa-miR-373-5p gene" or "hsa-miR-373-5p" include the hsa-miR-373-5p gene (miRBase Accession No. MIMAT0000725) described in Sequence ID No. 23, as well as other species homologs or orthologs. The hsa-miR-373-5p gene can be obtained by the method described by Suh MR et al., 2004, Dev Biol, Vol. 270, pp. 488-498. In addition, "hsa-miR-373-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-373" (miRBase Accession No. MI0000781, Sequence ID No. 300).

[0105] As used herein, the terms "hsa-miR-1268a gene" or "hsa-miR-1268a" include the hsa-miR-1268a gene (miRBase Accession No. MIMAT0005922) described in Sequence ID No. 24, as well as other species homologs or orthologs. The hsa-miR-1268a gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1268a" is known to have a hairpin-like structure as its precursor, "hsa-mir-1268a" (miRBase Accession No. MI0006405, Sequence ID No. 301).

[0106] As used herein, the terms "hsa-miR-1260b gene" or "hsa-miR-1260b" include the hsa-miR-1260b gene (miRBase Accession No. MIMAT0015041) described in Sequence ID No. 25, as well as other species homologs or orthologs. The hsa-miR-1260b gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-1260b" is known to have a hairpin-like structure as its precursor, "hsa-mir-1260b" (miRBase Accession No. MI0014197, Sequence ID No. 302).

[0107] As used herein, the terms "hsa-miR-4258 gene" or "hsa-miR-4258" include the hsa-miR-4258 gene (miRBase Accession No. MIMAT0016879) described in Sequence ID No. 26, as well as other species homologs or orthologs. The hsa-miR-4258 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4258" is known to have a hairpin-like structure as its precursor, "hsa-mir-4258" (miRBase Accession No. MI0015857, Sequence ID No. 303).

[0108] As used herein, the terms "hsa-miR-4697-5p gene" or "hsa-miR-4697-5p" include the hsa-miR-4697-5p gene (miRBase Accession No. MIMAT0019791) described in Sequence ID No. 27, as well as other species homologs or orthologs. The hsa-miR-4697-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4697-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4697" (miRBase Accession No. MI0017330, Sequence ID No. 304).

[0109] As used herein, the terms "hsa-miR-1469 gene" or "hsa-miR-1469" include the hsa-miR-1469 gene (miRBase Accession No. MIMAT0007347) described in Sequence ID No. 28, as well as other species homologs or orthologs. The hsa-miR-1469 gene can be obtained by the method described by Kawaji H et al., 2008, BMC Genomics, Vol. 9, p. 157. In addition, "hsa-miR-1469" is known to have a hairpin-like structure as its precursor, "hsa-mir-1469" (miRBase Accession No. MI0007074, Sequence ID No. 305).

[0110] As used herein, the terms "hsa-miR-4515 gene" or "hsa-miR-4515" include the hsa-miR-4515 gene (miRBase Accession No. MIMAT0019052) described in Sequence ID No. 29, as well as other species homologs or orthologs. The hsa-miR-4515 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4515" is known to have a hairpin-like structure as its precursor, "hsa-mir-4515" (miRBase Accession No. MI0016881, Sequence ID No. 306).

[0111] As used herein, the terms "hsa-miR-6861-5p gene" or "hsa-miR-6861-5p" include the hsa-miR-6861-5p gene (miRBase Accession No. MIMAT0027623) described in Sequence ID No. 30, as well as other species homologs or orthologs. The hsa-miR-6861-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6861-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6861" (miRBase Accession No. MI0022708, Sequence ID No. 307).

[0112] As used herein, the terms "hsa-miR-6821-5p gene" or "hsa-miR-6821-5p" include the hsa-miR-6821-5p gene (miRBase Accession No. MIMAT0027542) described in Sequence ID No. 31, as well as other species homologs or orthologs. The hsa-miR-6821-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6821-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6821" (miRBase Accession No. MI0022666, Sequence ID No. 308).

[0113] As used herein, the terms "hsa-miR-575 gene" or "hsa-miR-575" include the hsa-miR-575 gene described in Sequence ID No. 32 (miRBase Accession No. MIMAT0003240) and other species homologs or orthologs. The hsa-miR-575 gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-575" is known to have a hairpin-like structure as its precursor, "hsa-mir-575" (miRBase Accession No. MI0003582, Sequence ID No. 309).

[0114] As used herein, the terms "hsa-miR-6805-5p gene" or "hsa-miR-6805-5p" include the hsa-miR-6805-5p gene (miRBase Accession No. MIMAT0027510) described in Sequence ID No. 33, as well as other species homologs or orthologs. The hsa-miR-6805-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6805-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6805" (miRBase Accession No. MI0022650, Sequence ID No. 310).

[0115] As used herein, the terms "hsa-miR-4758-5p gene" or "hsa-miR-4758-5p" include the hsa-miR-4758-5p gene (miRBase Accession No. MIMAT0019903) described in Sequence ID No. 34, as well as other species homologs or orthologs. The hsa-miR-4758-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4758-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4758" (miRBase Accession No. MI0017399, Sequence ID No. 311).

[0116] As used herein, the terms "hsa-miR-3663-3p gene" or "hsa-miR-3663-3p" include the hsa-miR-3663-3p gene (miRBase Accession No. MIMAT0018085) described in Sequence ID No. 35, as well as other species homologs or orthologs. The hsa-miR-3663-3p gene can be obtained by the method described by Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3663-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3663" (miRBase Accession No. MI0016064, Sequence ID No. 312).

[0117] As used herein, the terms "hsa-miR-4530 gene" or "hsa-miR-4530" include the hsa-miR-4530 gene (miRBase Accession No. MIMAT0019069) described in Sequence ID No. 36, as well as other species homologs or orthologs. The hsa-miR-4530 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4530" is known to have a hairpin-like structure as its precursor, "hsa-mir-4530" (miRBase Accession No. MI0016897, Sequence ID No. 313).

[0118] As used herein, the terms "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" include the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in Sequence ID No. 37, as well as other species homologs or orthologs. The hsa-miR-6798-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6798-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6798" (miRBase Accession No. MI0022643, Sequence ID No. 314).

[0119] As used herein, the terms "hsa-miR-6781-5p gene" or "hsa-miR-6781-5p" include the hsa-miR-6781-5p gene (miRBase Accession No. MIMAT0027462) described in Sequence ID No. 38, as well as other species homologs or orthologs. The hsa-miR-6781-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6781-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6781" (miRBase Accession No. MI0022626, Sequence ID No. 315).

[0120] As used herein, the terms "hsa-miR-885-3p gene" or "hsa-miR-885-3p" include the hsa-miR-885-3p gene (miRBase Accession No. MIMAT0004948) described in Sequence ID No. 39, as well as other species homologs or orthologs. The hsa-miR-885-3p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-885-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-885" (miRBase Accession No. MI0005560, Sequence ID No. 316).

[0121] As used herein, the terms "hsa-miR-1273g-3p gene" or "hsa-miR-1273g-3p" include the hsa-miR-1273g-3p gene (miRBase Accession No. MIMAT0022742) described in Sequence ID No. 40, as well as other species homologs or orthologs. The hsa-miR-1273g-3p gene can be obtained by the method described by Reshmi G et al., 2011, Genomics, Vol. 97, pp. 333-340. In addition, "hsa-miR-1273g-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1273g" (miRBase Accession No. MI0018003, Sequence ID No. 317).

[0122] As used herein, the terms "hsa-miR-4787-3p gene" or "hsa-miR-4787-3p" include the hsa-miR-4787-3p gene (miRBase Accession No. MIMAT0019957) described in Sequence ID No. 41, as well as other species homologs or orthologs. The hsa-miR-4787-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4787-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4787" (miRBase Accession No. MI0017434, Sequence ID No. 318).

[0123] As used herein, the terms "hsa-miR-4454 gene" or "hsa-miR-4454" include the hsa-miR-4454 gene (miRBase Accession No. MIMAT0018976) described in Sequence ID No. 42, as well as other species homologs or orthologs. The hsa-miR-4454 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4454" is known to have a hairpin-like structure as its precursor, "hsa-mir-4454" (miRBase Accession No. MI0016800, Sequence ID No. 319).

[0124] As used herein, the terms "hsa-miR-4706 gene" or "hsa-miR-4706" include the hsa-miR-4706 gene (miRBase Accession No. MIMAT0019806) described in Sequence ID No. 43, as well as other species homologs or orthologs. The hsa-miR-4706 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4706" is known to have a hairpin-like structure as its precursor, "hsa-mir-4706" (miRBase Accession No. MI0017339, Sequence ID No. 320).

[0125] As used herein, the terms "hsa-miR-1249-3p gene" or "hsa-miR-1249-3p" include the hsa-miR-1249-3p gene (miRBase Accession No. MIMAT0005901) described in Sequence ID No. 44, as well as other species homologs or orthologs. The hsa-miR-1249-3p gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1249-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1249" (miRBase Accession No. MI0006384, Sequence ID No. 321).

[0126] As used herein, the terms "hsa-miR-887-3p gene" or "hsa-miR-887-3p" include the hsa-miR-887-3p gene (miRBase Accession No. MIMAT0004951) described in Sequence ID No. 45, as well as other species homologs or orthologs. The hsa-miR-887-3p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-887-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-887" (miRBase Accession No. MI0005562, Sequence ID No. 322).

[0127] As used herein, the terms "hsa-miR-6786-5p gene" or "hsa-miR-6786-5p" include the hsa-miR-6786-5p gene (miRBase Accession No. MIMAT0027472) described in Sequence ID No. 46, as well as other species homologs or orthologs. The hsa-miR-6786-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6786-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6786" (miRBase Accession No. MI0022631, Sequence ID No. 323).

[0128] As used herein, the terms "hsa-miR-1238-5p gene" or "hsa-miR-1238-5p" include the hsa-miR-1238-5p gene (miRBase Accession No. MIMAT0022947) described in Sequence ID No. 47, as well as other species homologs or orthologs. The hsa-miR-1238-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1238" (miRBase Accession No. MI0006328, Sequence ID No. 324), which has a hairpin-like structure, is known as a precursor of "hsa-miR-1238-5p".

[0129] As used herein, the terms "hsa-miR-6749-5p gene" or "hsa-miR-6749-5p" include the hsa-miR-6749-5p gene (miRBase Accession No. MIMAT0027398) described in Sequence ID No. 48, as well as other species homologs or orthologs. The hsa-miR-6749-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6749-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6749" (miRBase Accession No. MI0022594, Sequence ID No. 325).

[0130] As used herein, the terms "hsa-miR-6729-5p gene" or "hsa-miR-6729-5p" include the hsa-miR-6729-5p gene (miRBase Accession No. MIMAT0027359) described in Sequence ID No. 49, as well as other species homologs or orthologs. The hsa-miR-6729-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6729-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6729" (miRBase Accession No. MI0022574, Sequence ID No. 326).

[0131] The terms "hsa-miR-6825-5p gene" or "hsa-miR-6825-5p" as used herein include the hsa-miR-6825-5p gene (miRBase Accession No. MIMAT0027550) described in Sequence ID No. 50, as well as other species homologs or orthologs. The hsa-miR-6825-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6825-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6825" (miRBase Accession No. MI0022670, Sequence ID No. 327).

[0132] As used herein, the terms "hsa-miR-663b gene" or "hsa-miR-663b" include the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) described in Sequence ID No. 51, as well as other species homologs or orthologs. The hsa-miR-663b gene can be obtained by the method described by Takada S et al., 2008, Leukemia, Vol. 22, pp. 1274-1278. In addition, "hsa-miR-663b" is known to have a hairpin-like structure as its precursor, "hsa-mir-663b" (miRBase Accession No. MI0006336, Sequence ID No. 328).

[0133] As used herein, the terms "hsa-miR-6858-5p gene" or "hsa-miR-6858-5p" include the hsa-miR-6858-5p gene (miRBase Accession No. MIMAT0027616) described in Sequence ID No. 52, as well as other species homologs or orthologs. The hsa-miR-6858-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6858-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6858" (miRBase Accession No. MI0022704, Sequence ID No. 329).

[0134] As used herein, the terms "hsa-miR-4690-5p gene" or "hsa-miR-4690-5p" include the hsa-miR-4690-5p gene (miRBase Accession No. MIMAT0019779) described in Sequence ID No. 53, as well as other species homologs or orthologs. The hsa-miR-4690-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4690-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4690" (miRBase Accession No. MI0017323, Sequence ID No. 330).

[0135] As used herein, the terms "hsa-miR-6765-5p gene" or "hsa-miR-6765-5p" include the hsa-miR-6765-5p gene (miRBase Accession No. MIMAT0027430) described in Sequence ID No. 54, as well as other species homologs or orthologs. The hsa-miR-6765-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6765-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6765" (miRBase Accession No. MI0022610, Sequence ID No. 331).

[0136] As used herein, the terms "hsa-miR-4710 gene" or "hsa-miR-4710" include the hsa-miR-4710 gene (miRBase Accession No. MIMAT0019815) described in Sequence ID No. 55, as well as other species homologs or orthologs. The hsa-miR-4710 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4710" is known to have a hairpin-like structure as its precursor, "hsa-mir-4710" (miRBase Accession No. MI0017344, Sequence ID No. 332).

[0137] The terms "hsa-miR-6775-5p gene" or "hsa-miR-6775-5p" as used herein include the hsa-miR-6775-5p gene (miRBase Accession No. MIMAT0027450) described in Sequence ID No. 56, as well as other species homologs or orthologs. The hsa-miR-6775-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6775-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6775" (miRBase Accession No. MI0022620, Sequence ID No. 333).

[0138] As used herein, the terms "hsa-miR-371a-5p gene" or "hsa-miR-371a-5p" include the hsa-miR-371a-5p gene (miRBase Accession No. MIMAT0004687) described in Sequence ID No. 57, as well as other species homologs or orthologs. The hsa-miR-371a-5p gene can be obtained by the method described by Suh MR et al., 2004, Dev Biol, Vol. 270, pp. 488-498. In addition, "hsa-miR-371a-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-371a" (miRBase Accession No. MI0000779, Sequence ID No. 334).

[0139] As used herein, the terms "hsa-miR-6816-5p gene" or "hsa-miR-6816-5p" include the hsa-miR-6816-5p gene (miRBase Accession No. MIMAT0027532) described in Sequence ID No. 58, as well as other species homologs or orthologs. The hsa-miR-6816-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6816-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6816" (miRBase Accession No. MI0022661, Sequence ID No. 335).

[0140] As used herein, the terms "hsa-miR-296-3p gene" or "hsa-miR-296-3p" include the hsa-miR-296-3p gene (miRBase Accession No. MIMAT0004679) described in Sequence ID No. 59, as well as other species homologs or orthologs. The hsa-miR-296-3p gene can be obtained by the method described by Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358. In addition, "hsa-miR-296-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-296" (miRBase Accession No. MI0000747, Sequence ID No. 336).

[0141] As used herein, the terms "hsa-miR-7977 gene" or "hsa-miR-7977" include the hsa-miR-7977 gene (miRBase Accession No. MIMAT0031180) described in Sequence ID No. 60, as well as other species homologs or orthologs. The hsa-miR-7977 gene can be obtained by the method described by Velthut-Meikas A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141. In addition, "hsa-miR-7977" is known to have a hairpin-like structure as its precursor, "hsa-mir-7977" (miRBase Accession No. MI0025753, Sequence ID No. 337).

[0142] As used herein, the terms "hsa-miR-8069 gene" or "hsa-miR-8069" include the hsa-miR-8069 gene described in Sequence ID No. 61 (miRBase Accession No. MIMAT0030996) and other species homologs or orthologs. The hsa-miR-8069 gene can be obtained by the method described by Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8069" is known to have hairpin-like precursors, "hsa-mir-8069-1, hsa-mir-8069-2" (miRBase Accession No. MI0025905, MI0031519, Sequence IDs 338, 339).

[0143] As used herein, the terms "hsa-miR-6515-3p gene" or "hsa-miR-6515-3p" include the hsa-miR-6515-3p gene (miRBase Accession No. MIMAT0025487) described in Sequence ID No. 62, as well as other species homologs or orthologs. The hsa-miR-6515-3p gene can be obtained by the method described by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. In addition, "hsa-miR-6515-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6515" (miRBase Accession No. MI0022227, Sequence ID No. 340).

[0144] As used herein, the terms "hsa-miR-4687-5p gene" or "hsa-miR-4687-5p" include the hsa-miR-4687-5p gene (miRBase Accession No. MIMAT0019774) described in Sequence ID No. 63, as well as other species homologs or orthologs. The hsa-miR-4687-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4687-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4687" (miRBase Accession No. MI0017319, Sequence ID No. 341).

[0145] As used herein, the terms "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" include the hsa-miR-1343-5p gene (miRBase Accession No. MIMAT0027038) described in Sequence ID No. 64, as well as other species homologs or orthologs. The hsa-miR-1343-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-1343-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1343" (miRBase Accession No. MI0017320, Sequence ID No. 294).

[0146] As used herein, the terms "hsa-miR-7110-5p gene" or "hsa-miR-7110-5p" include the hsa-miR-7110-5p gene (miRBase Accession No. MIMAT0028117) described in Sequence ID No. 65, as well as other species homologs or orthologs. The hsa-miR-7110-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-7110-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-7110" (miRBase Accession No. MI0022961, Sequence ID No. 342).

[0147] As used herein, the terms "hsa-miR-4525 gene" or "hsa-miR-4525" include the hsa-miR-4525 gene (miRBase Accession No. MIMAT0019064) described in Sequence ID No. 66, as well as other species homologs or orthologs. The hsa-miR-4525 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4525" is known to have a hairpin-like structure as its precursor, "hsa-mir-4525" (miRBase Accession No. MI0016892, Sequence ID No. 343).

[0148] As used herein, the terms "hsa-miR-3158-5p gene" or "hsa-miR-3158-5p" include the hsa-miR-3158-5p gene (miRBase Accession No. MIMAT0019211) described in Sequence ID No. 67, as well as other species homologs or orthologs. The hsa-miR-3158-5p gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3158-5p" is known to have hairpin-like precursors, "hsa-mir-3158-1, hsa-mir-3158-2" (miRBase Accession No. MI0014186, MI0014187, Sequence ID No. 344, 345).

[0149] As used herein, the terms "hsa-miR-6787-5p gene" or "hsa-miR-6787-5p" include the hsa-miR-6787-5p gene (miRBase Accession No. MIMAT0027474) described in Sequence ID No. 68, as well as other species homologs or orthologs. The hsa-miR-6787-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6787-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6787" (miRBase Accession No. MI0022632, Sequence ID No. 346).

[0150] As used herein, the terms "hsa-miR-614 gene" or "hsa-miR-614" include the hsa-miR-614 gene (miRBase Accession No. MIMAT0003282) described in Sequence ID No. 69, as well as other species homologs or orthologs. The hsa-miR-614 gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-614" is known to have a hairpin-like structure as its precursor, "hsa-mir-614" (miRBase Accession No. MI0003627, Sequence ID No. 347).

[0151] As used herein, the terms "hsa-miR-4689 gene" or "hsa-miR-4689" include the hsa-miR-4689 gene (miRBase Accession No. MIMAT0019778) described in Sequence ID No. 70, as well as other species homologs or orthologs. The hsa-miR-4689 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4689" is known to have a hairpin-like structure as its precursor, "hsa-mir-4689" (miRBase Accession No. MI0017322, Sequence ID No. 348).

[0152] As used herein, the terms "hsa-miR-1185-2-3p gene" or "hsa-miR-1185-2-3p" include the hsa-miR-1185-2-3p gene (miRBase Accession No. MIMAT0022713) described in Sequence ID No. 71, as well as other species homologs or orthologs. The hsa-miR-1185-2-3p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-1185-2" is known to have a hairpin-like structure as its precursor, "hsa-mir-1185-2" (miRBase Accession No. MI0003821, Sequence ID No. 349).

[0153] As used herein, the terms "hsa-miR-1268b gene" or "hsa-miR-1268b" include the hsa-miR-1268b gene (miRBase Accession No. MIMAT0018925) described in Sequence ID No. 72, as well as other species homologs or orthologs. The hsa-miR-1268b gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-1268b" is known to have a hairpin-like structure as its precursor, "hsa-mir-1268b" (miRBase Accession No. MI0016748, Sequence ID No. 350).

[0154] As used herein, the terms "hsa-miR-1228-3p gene" or "hsa-miR-1228-3p" include the hsa-miR-1228-3p gene (miRBase Accession No. MIMAT0005583) described in Sequence ID No. 73, as well as other species homologs or orthologs. The hsa-miR-1228-3p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1228" (miRBase Accession No. MI0006318, Sequence ID No. 278), which has a hairpin-like structure, is known as a precursor of "hsa-miR-1228-3p".

[0155] As used herein, the terms "hsa-miR-1185-1-3p gene" or "hsa-miR-1185-1-3p" include the hsa-miR-1185-1-3p gene (miRBase Accession No. MIMAT0022838) described in Sequence ID No. 74, as well as other species homologs or orthologs. The hsa-miR-1185-1-3p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-1185-1" (miRBase Accession No. MI0003844, Sequence ID No. 351), which has a hairpin-like structure, is known as a precursor of "hsa-miR-1185-1-3p".

[0156] As used herein, the terms "hsa-miR-940 gene" or "hsa-miR-940" include the hsa-miR-940 gene (miRBase Accession No. MIMAT0004983) described in Sequence ID No. 75, as well as other species homologs or orthologs. The hsa-miR-940 gene can be obtained by the method described by Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. In addition, "hsa-miR-940" is known to have a hairpin-like structure as its precursor, "hsa-mir-940" (miRBase Accession No. MI0005762, Sequence ID No. 352).

[0157] As used herein, the terms "hsa-miR-939-5p gene" or "hsa-miR-939-5p" include the hsa-miR-939-5p gene (miRBase Accession No. MIMAT0004982) described in Sequence ID No. 76, as well as other species homologs or orthologs. The hsa-miR-939-5p gene can be obtained by the method described by Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. In addition, "hsa-miR-939-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-939" (miRBase Accession No. MI0005761, Sequence ID No. 353).

[0158] As used herein, the terms "hsa-miR-6757-5p gene" or "hsa-miR-6757-5p" include the hsa-miR-6757-5p gene (miRBase Accession No. MIMAT0027414) described in Sequence ID No. 77, as well as other species homologs or orthologs. The hsa-miR-6757-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6757-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6757" (miRBase Accession No. MI0022602, Sequence ID No. 354).

[0159] As used herein, the terms "hsa-miR-1275 gene" or "hsa-miR-1275" include the hsa-miR-1275 gene (miRBase Accession No. MIMAT0005929) described in Sequence ID No. 78, as well as other species homologs or orthologs. The hsa-miR-1275 gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1275" is known to have a hairpin-like structure as its precursor, "hsa-mir-1275" (miRBase Accession No. MI0006415, Sequence ID No. 355).

[0160] As used herein, the terms "hsa-miR-5001-5p gene" or "hsa-miR-5001-5p" include the hsa-miR-5001-5p gene (miRBase Accession No. MIMAT0021021) described in Sequence ID No. 79, as well as other species homologs or orthologs. The hsa-miR-5001-5p gene can be obtained by the method described by Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. In addition, "hsa-miR-5001-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-5001" (miRBase Accession No. MI0017867, Sequence ID No. 356).

[0161] As used herein, the terms "hsa-miR-6826-5p gene" or "hsa-miR-6826-5p" include the hsa-miR-6826-5p gene (miRBase Accession No. MIMAT0027552) described in Sequence ID No. 80, as well as other species homologs or orthologs. The hsa-miR-6826-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6826-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6826" (miRBase Accession No. MI0022671, Sequence ID No. 357).

[0162] As used herein, the terms "hsa-miR-6765-3p gene" or "hsa-miR-6765-3p" include the hsa-miR-6765-3p gene (miRBase Accession No. MIMAT0027431) described in Sequence ID No. 81, as well as other species homologs or orthologs. The hsa-miR-6765-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6765-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6765" (miRBase Accession No. MI0022610, Sequence ID No. 331).

[0163] As used herein, the terms "hsa-miR-3679-3p gene" or "hsa-miR-3679-3p" include the hsa-miR-3679-3p gene (miRBase Accession No. MIMAT0018105) described in Sequence ID No. 82, as well as other species homologs or orthologs. The hsa-miR-3679-3p gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3679-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3679" (miRBase Accession No. MI0016080, Sequence ID No. 358).

[0164] As used herein, the terms "hsa-miR-4718 gene" or "hsa-miR-4718" include the hsa-miR-4718 gene (miRBase Accession No. MIMAT0019831) described in Sequence ID No. 83, as well as other species homologs or orthologs. The hsa-miR-4718 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4718" is known to have a hairpin-like structure as its precursor, "hsa-mir-4718" (miRBase Accession No. MI0017353, Sequence ID No. 359).

[0165] As used herein, the terms "hsa-miR-4286 gene" or "hsa-miR-4286" include the hsa-miR-4286 gene (miRBase Accession No. MIMAT0016916) described in Sequence ID No. 84, as well as other species homologs or orthologs. The hsa-miR-4286 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4286" is known to have a hairpin-like structure as its precursor, "hsa-mir-4286" (miRBase Accession No. MI0015894, Sequence ID No. 360).

[0166] As used herein, the terms "hsa-miR-8059 gene" or "hsa-miR-8059" include the hsa-miR-8059 gene (miRBase Accession No. MIMAT0030986) described in Sequence ID No. 85, as well as other species homologs or orthologs. The hsa-miR-8059 gene can be obtained by the method described by Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8059" is known to have a hairpin-like structure as its precursor, "hsa-mir-8059" (miRBase Accession No. MI0025895, Sequence ID No. 361).

[0167] As used herein, the terms "hsa-miR-4447 gene" or "hsa-miR-4447" include the hsa-miR-4447 gene (miRBase Accession No. MIMAT0018966) described in Sequence ID No. 86, as well as other species homologs or orthologs. The hsa-miR-4447 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4447" is known to have a hairpin-like structure as its precursor, "hsa-mir-4447" (miRBase Accession No. MI0016790, Sequence ID No. 362).

[0168] As used herein, the terms "hsa-miR-4448 gene" or "hsa-miR-4448" include the hsa-miR-4448 gene (miRBase Accession No. MIMAT0018967) described in Sequence ID No. 87, as well as other species homologs or orthologs. The hsa-miR-4448 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4448" is known to have a hairpin-like structure as its precursor, "hsa-mir-4448" (miRBase Accession No. MI0016791, Sequence ID No. 363).

[0169] As used herein, the terms "hsa-miR-658 gene" or "hsa-miR-658" include the hsa-miR-658 gene (miRBase Accession No. MIMAT0003336) described in Sequence ID No. 88, as well as other species homologs or orthologs. The hsa-miR-658 gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-658" is known to have a hairpin-like structure as its precursor, "hsa-mir-658" (miRBase Accession No. MI0003682, Sequence ID No. 364).

[0170] As used herein, the terms "hsa-miR-6766-3p gene" or "hsa-miR-6766-3p" include the hsa-miR-6766-3p gene (miRBase Accession No. MIMAT0027433) described in Sequence ID No. 89, as well as other species homologs or orthologs. The hsa-miR-6766-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6766-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6766" (miRBase Accession No. MI0022611, Sequence ID No. 365).

[0171] As used herein, the terms "hsa-miR-197-5p gene" or "hsa-miR-197-5p" include the hsa-miR-197-5p gene (miRBase Accession No. MIMAT0022691) described in Sequence ID No. 90, as well as other species homologs or orthologs. The hsa-miR-197-5p gene can be obtained by the method described by Lagos-Quintana M et al., 2003, RNA, Vol. 9, pp. 175-179. In addition, "hsa-miR-197-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-197" (miRBase Accession No. MI0000239, Sequence ID No. 366).

[0172] As used herein, the terms "hsa-miR-6887-5p gene" or "hsa-miR-6887-5p" include the hsa-miR-6887-5p gene (miRBase Accession No. MIMAT0027674) described in Sequence ID No. 91, as well as other species homologs or orthologs. The hsa-miR-6887-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6887-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6887" (miRBase Accession No. MI0022734, Sequence ID No. 367).

[0173] As used herein, the terms "hsa-miR-6742-5p gene" or "hsa-miR-6742-5p" include the hsa-miR-6742-5p gene (miRBase Accession No. MIMAT0027385) described in Sequence ID No. 92, as well as other species homologs or orthologs. The hsa-miR-6742-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6742-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6742" (miRBase Accession No. MI0022587, Sequence ID No. 368).

[0174] As used herein, the terms "hsa-miR-6729-3p gene" or "hsa-miR-6729-3p" include the hsa-miR-6729-3p gene (miRBase Accession No. MIMAT0027360) described in Sequence ID No. 93, as well as other species homologs or orthologs. The hsa-miR-6729-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6729-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6729" (miRBase Accession No. MI0022574, Sequence ID No. 326).

[0175] As used herein, the terms "hsa-miR-5090 gene" or "hsa-miR-5090" include the hsa-miR-5090 gene (miRBase Accession No. MIMAT0021082) described in Sequence ID No. 94, as well as other species homologs or orthologs. The hsa-miR-5090 gene can be obtained by the method described by Ding N et al., 2011, J Radiat Res, Vol. 52, pp. 425-432. In addition, "hsa-miR-5090" is known to have a hairpin-like structure as its precursor, "hsa-mir-5090" (miRBase Accession No. MI0017979, Sequence ID No. 369).

[0176] As used herein, the terms "hsa-miR-7975 gene" or "hsa-miR-7975" include the hsa-miR-7975 gene (miRBase Accession No. MIMAT0031178) described in Sequence ID No. 95, as well as other species homologs or orthologs. The hsa-miR-7975 gene can be obtained by the method described by Velthut-Meikas A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141. In addition, "hsa-miR-7975" is known to have a hairpin-like structure as its precursor, "hsa-mir-7975" (miRBase Accession No. MI0025751, Sequence ID No. 370).

[0177] As used herein, the terms "hsa-miR-4505 gene" or "hsa-miR-4505" include the hsa-miR-4505 gene (miRBase Accession No. MIMAT0019041) described in Sequence ID No. 96, as well as other species homologs or orthologs. The hsa-miR-4505 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4505" is known to have a hairpin-like structure as its precursor, "hsa-mir-4505" (miRBase Accession No. MI0016868, Sequence ID No. 371).

[0178] As used herein, the terms "hsa-miR-6889-5p gene" or "hsa-miR-6889-5p" include the hsa-miR-6889-5p gene (miRBase Accession No. MIMAT0027678) described in Sequence ID No. 97, as well as other species homologs or orthologs. The hsa-miR-6889-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6889-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6889" (miRBase Accession No. MI0022736, Sequence ID No. 372).

[0179] As used herein, the terms "hsa-miR-4708-3p gene" or "hsa-miR-4708-3p" include the hsa-miR-4708-3p gene (miRBase Accession No. MIMAT0019810) described in Sequence ID No. 98, as well as other species homologs or orthologs. The hsa-miR-4708-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4708-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4708" (miRBase Accession No. MI0017341, Sequence ID No. 373).

[0180] As used herein, the terms "hsa-miR-6131 gene" or "hsa-miR-6131" include the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in Sequence ID No. 99, as well as other species homologs or orthologs. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, pp. 552-564. In addition, "hsa-miR-6131" is known to have a hairpin-like structure as its precursor, "hsa-mir-6131" (miRBase Accession No. MI0021276, Sequence ID No. 374).

[0181] As used herein, the terms "hsa-miR-1225-3p gene" or "hsa-miR-1225-3p" include the hsa-miR-1225-3p gene (miRBase Accession No. MIMAT0005573) described in Sequence ID No. 100, as well as other species homologs or orthologs. The hsa-miR-1225-3p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1225-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1225" (miRBase Accession No. MI0006311, Sequence ID No. 375).

[0182] As used herein, the terms "hsa-miR-6132 gene" or "hsa-miR-6132" include the hsa-miR-6132 gene (miRBase Accession No. MIMAT0024616) described in Sequence ID No. 101, as well as other species homologs or orthologs. The hsa-miR-6132 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, pp. 552-564. In addition, "hsa-miR-6132" is known to have a hairpin-like structure as its precursor, "hsa-mir-6132" (miRBase Accession No. MI0021277, Sequence ID No. 376).

[0183] As used herein, the terms "hsa-miR-4734 gene" or "hsa-miR-4734" include the hsa-miR-4734 gene (miRBase Accession No. MIMAT0019859) described in Sequence ID No. 102, as well as other species homologs or orthologs. The hsa-miR-4734 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4734" is known to have a hairpin-like structure as its precursor, "hsa-mir-4734" (miRBase Accession No. MI0017371, Sequence ID No. 377).

[0184] As used herein, the terms "hsa-miR-3194-3p gene" or "hsa-miR-3194-3p" include the hsa-miR-3194-3p gene (miRBase Accession No. MIMAT0019218) described in Sequence ID No. 103, as well as other species homologs or orthologs. The hsa-miR-3194-3p gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3194-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3194" (miRBase Accession No. MI0014239, Sequence ID No. 378).

[0185] As used herein, the terms "hsa-miR-638 gene" or "hsa-miR-638" include the hsa-miR-638 gene (miRBase Accession No. MIMAT0003308) described in Sequence ID No. 104, as well as other species homologs or orthologs. The hsa-miR-638 gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-638" is known to have a hairpin-like structure as its precursor, "hsa-mir-638" (miRBase Accession No. MI0003653, Sequence ID No. 379).

[0186] As used herein, the terms "hsa-miR-2467-3p gene" or "hsa-miR-2467-3p" include the hsa-miR-2467-3p gene (miRBase Accession No. MIMAT0019953) described in Sequence ID No. 105, as well as other species homologs or orthologs. The hsa-miR-2467-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-2467-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-2467" (miRBase Accession No. MI0017432, Sequence ID No. 380).

[0187] As used herein, the terms "hsa-miR-4728-5p gene" or "hsa-miR-4728-5p" include the hsa-miR-4728-5p gene (miRBase Accession No. MIMAT0019849) described in Sequence ID No. 106, as well as other species homologs or orthologs. The hsa-miR-4728-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4728-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4728" (miRBase Accession No. MI0017365, Sequence ID No. 381).

[0188] As used herein, the terms "hsa-miR-5572 gene" or "hsa-miR-5572" include the hsa-miR-5572 gene (miRBase Accession No. MIMAT0022260) described in Sequence ID No. 107, as well as other species homologs or orthologs. The hsa-miR-5572 gene can be obtained by the method described by Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. In addition, "hsa-miR-5572" is known to have a hairpin-like structure as its precursor, "hsa-mir-5572" (miRBase Accession No. MI0019117, Sequence ID No. 382).

[0189] As used herein, the terms "hsa-miR-6789-5p gene" or "hsa-miR-6789-5p" include the hsa-miR-6789-5p gene (miRBase Accession No. MIMAT0027478) described in Sequence ID No. 108, as well as other species homologs or orthologs. The hsa-miR-6789-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6789-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6789" (miRBase Accession No. MI0022634, Sequence ID No. 383).

[0190] As used herein, the terms "hsa-miR-8063 gene" or "hsa-miR-8063" include the hsa-miR-8063 gene (miRBase Accession No. MIMAT0030990) described in Sequence ID No. 109, as well as other species homologs or orthologs. The hsa-miR-8063 gene can be obtained by the method described by Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8063" is known to have a hairpin-like structure as its precursor, "hsa-mir-8063" (miRBase Accession No. MI0025899, Sequence ID No. 384).

[0191] As used herein, the terms "hsa-miR-4429 gene" or "hsa-miR-4429" include the hsa-miR-4429 gene (miRBase Accession No. MIMAT0018944) described in Sequence ID No. 110, as well as other species homologs or orthologs. The hsa-miR-4429 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4429" is known to have a hairpin-like structure as its precursor, "hsa-mir-4429" (miRBase Accession No. MI0016768, Sequence ID No. 385).

[0192] As used herein, the terms "hsa-miR-6840-3p gene" or "hsa-miR-6840-3p" include the hsa-miR-6840-3p gene (miRBase Accession No. MIMAT0027583) described in Sequence ID No. 111, as well as other species homologs or orthologs. The hsa-miR-6840-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6840-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6840" (miRBase Accession No. MI0022686, Sequence ID No. 386).

[0193] As used herein, the terms "hsa-miR-4476 gene" or "hsa-miR-4476" include the hsa-miR-4476 gene (miRBase Accession No. MIMAT0019003) described in Sequence ID No. 112, as well as other species homologs or orthologs. The hsa-miR-4476 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4476" is known to have a hairpin-like structure as its precursor, "hsa-mir-4476" (miRBase Accession No. MI0016828, Sequence ID No. 387).

[0194] As used herein, the terms "hsa-miR-675-5p gene" or "hsa-miR-675-5p" include the hsa-miR-675-5p gene (miRBase Accession No. MIMAT0004284) described in Sequence ID No. 113, as well as other species homologs or orthologs. The hsa-miR-675-5p gene can be obtained by the method described in Cai X et al., 2007, RNA, Vol. 13, pp. 313-316. Furthermore, "hsa-miR-675-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-675" (miRBase Accession No. MI0005416, Sequence ID No. 388).

[0195] As used herein, the terms "hsa-miR-711 gene" or "hsa-miR-711" include the hsa-miR-711 gene (miRBase Accession No. MIMAT0012734) described in Sequence ID No. 114, as well as other species homologs or orthologs. The hsa-miR-711 gene can be obtained by the method described by Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. In addition, "hsa-miR-711" is known to have a hairpin-like structure as its precursor, "hsa-mir-711" (miRBase Accession No. MI0012488, Sequence ID No. 389).

[0196] As used herein, the terms "hsa-miR-6875-5p gene" or "hsa-miR-6875-5p" include the hsa-miR-6875-5p gene (miRBase Accession No. MIMAT0027650) described in Sequence ID No. 115, as well as other species homologs or orthologs. The hsa-miR-6875-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6875-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6875" (miRBase Accession No. MI0022722, Sequence ID No. 390).

[0197] As used herein, the terms "hsa-miR-3160-5p gene" or "hsa-miR-3160-5p" include the hsa-miR-3160-5p gene (miRBase Accession No. MIMAT0019212) described in Sequence ID No. 116, as well as other species homologs or orthologs. The hsa-miR-3160-5p gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3160-5p" is known to have hairpin-like precursors, "hsa-mir-3160-1, hsa-mir-3160-2" (miRBase Accession No. MI0014189, MI0014190, Sequence ID No. 391, 392).

[0198] As used herein, the terms "hsa-miR-1908-5p gene" or "hsa-miR-1908-5p" include the hsa-miR-1908-5p gene (miRBase Accession No. MIMAT0007881) described in Sequence ID No. 117, as well as other species homologs or orthologs. The hsa-miR-1908-5p gene can be obtained by the method described by Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, "hsa-miR-1908-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1908" (miRBase Accession No. MI0008329, Sequence ID No. 393).

[0199] The terms "hsa-miR-6726-5p gene" or "hsa-miR-6726-5p" as used herein include the hsa-miR-6726-5p gene (miRBase Accession No. MIMAT0027353) described in Sequence ID No. 118, as well as other species homologs or orthologs. The hsa-miR-6726-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6726-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6726" (miRBase Accession No. MI0022571, Sequence ID No. 394).

[0200] As used herein, the terms "hsa-miR-1913 gene" or "hsa-miR-1913" include the hsa-miR-1913 gene (miRBase Accession No. MIMAT0007888) described in Sequence ID No. 119, as well as other species homologs or orthologs. The hsa-miR-1913 gene can be obtained by the method described by Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, "hsa-miR-1913" is known to have a hairpin-like structure as its precursor, "hsa-mir-1913" (miRBase Accession No. MI0008334, Sequence ID No. 395).

[0201] As used herein, the terms "hsa-miR-8071 gene" or "hsa-miR-8071" include the hsa-miR-8071 gene (miRBase Accession No. MIMAT0030998) described in Sequence ID No. 120, as well as other species homologs or orthologs. The hsa-miR-8071 gene can be obtained by the method described by Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8071" is known to have hairpin-like precursors, "hsa-mir-8071-1, hsa-mir-8071-2" (miRBase Accession No. MI0025907, MI0026417, Sequence IDs 396, 397).

[0202] As used herein, the terms "hsa-miR-3648 gene" or "hsa-miR-3648" include the hsa-miR-3648 gene (miRBase Accession No. MIMAT0018068) described in Sequence ID No. 121, as well as other species homologs or orthologs. The hsa-miR-3648 gene can be obtained by the method described by Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, pp. 6234-6246. In addition, "hsa-miR-3648" is known to have hairpin-like precursors, "hsa-mir-3648-1, hsa-mir-3648-2" (miRBase Accession No. MI0016048, MI0031512, Sequence IDs 398, 399).

[0203] As used herein, the terms "hsa-miR-4732-5p gene" or "hsa-miR-4732-5p" include the hsa-miR-4732-5p gene (miRBase Accession No. MIMAT0019855) described in Sequence ID No. 122, as well as other species homologs or orthologs. The hsa-miR-4732-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4732-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4732" (miRBase Accession No. MI0017369, Sequence ID No. 400).

[0204] As used herein, the terms "hsa-miR-4787-5p gene" or "hsa-miR-4787-5p" include the hsa-miR-4787-5p gene (miRBase Accession No. MIMAT0019956) described in Sequence ID No. 123, as well as other species homologs or orthologs. The hsa-miR-4787-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4787-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4787" (miRBase Accession No. MI0017434, Sequence ID No. 318).

[0205] As used herein, the terms "hsa-miR-3917 gene" or "hsa-miR-3917" include the hsa-miR-3917 gene (miRBase Accession No. MIMAT0018191) described in Sequence ID No. 124, as well as other species homologs or orthologs. The hsa-miR-3917 gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3917" is known to have a hairpin-like structure as its precursor, "hsa-mir-3917" (miRBase Accession No. MI0016423, Sequence ID No. 401).

[0206] As used herein, the terms "hsa-miR-619-5p gene" or "hsa-miR-619-5p" include the hsa-miR-619-5p gene (miRBase Accession No. MIMAT0026622) described in Sequence ID No. 125, as well as other species homologs or orthologs. The hsa-miR-619-5p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-619-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-619" (miRBase Accession No. MI0003633, Sequence ID No. 402).

[0207] As used herein, the terms "hsa-miR-1231 gene" or "hsa-miR-1231" include the hsa-miR-1231 gene (miRBase Accession No. MIMAT0005586) described in Sequence ID No. 126, as well as other species homologs or orthologs. The hsa-miR-1231 gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1231" is known to have a hairpin-like structure as its precursor, "hsa-mir-1231" (miRBase Accession No. MI0006321, Sequence ID No. 403).

[0208] As used herein, the terms "hsa-miR-342-5p gene" or "hsa-miR-342-5p" include the hsa-miR-342-5p gene (miRBase Accession No. MIMAT0004694) described in Sequence ID No. 127, as well as other species homologs or orthologs. The hsa-miR-342-5p gene can be obtained by the method described by Kim J et al., 2004, Proc Natl Acad Sci USA, Vol. 101, pp. 360-365. In addition, "hsa-miR-342-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-342" (miRBase Accession No. MI0000805, Sequence ID No. 404).

[0209] As used herein, the terms "hsa-miR-4433a-5p gene" or "hsa-miR-4433a-5p" include the hsa-miR-4433a-5p gene (miRBase Accession No. MIMAT0020956) described in Sequence ID No. 128, as well as other species homologs or orthologs. The hsa-miR-4433a-5p gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4433a-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4433a" (miRBase Accession No. MI0016773, Sequence ID No. 405).

[0210] As used herein, the terms "hsa-miR-6766-5p gene" or "hsa-miR-6766-5p" include the hsa-miR-6766-5p gene (miRBase Accession No. MIMAT0027432) described in Sequence ID No. 129, as well as other species homologs or orthologs. The hsa-miR-6766-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6766-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6766" (miRBase Accession No. MI0022611, Sequence ID No. 365).

[0211] As used herein, the terms "hsa-miR-4707-5p gene" or "hsa-miR-4707-5p" include the hsa-miR-4707-5p gene (miRBase Accession No. MIMAT0019807) described in Sequence ID No. 130, as well as other species homologs or orthologs. The hsa-miR-4707-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4707-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4707" (miRBase Accession No. MI0017340, Sequence ID No. 406).

[0212] As used herein, the terms "hsa-miR-7114-5p gene" or "hsa-miR-7114-5p" include the hsa-miR-7114-5p gene (miRBase Accession No. MIMAT0028125) described in Sequence ID No. 131, as well as other species homologs or orthologs. The hsa-miR-7114-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-7114-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-7114" (miRBase Accession No. MI0022965, Sequence ID No. 407).

[0213] As used herein, the terms "hsa-miR-6872-3p gene" or "hsa-miR-6872-3p" include the hsa-miR-6872-3p gene (miRBase Accession No. MIMAT0027645) described in Sequence ID No. 132, as well as other species homologs or orthologs. The hsa-miR-6872-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6872-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6872" (miRBase Accession No. MI0022719, Sequence ID No. 408).

[0214] As used herein, the terms "hsa-miR-6780b-5p gene" or "hsa-miR-6780b-5p" include the hsa-miR-6780b-5p gene (miRBase Accession No. MIMAT0027572) described in Sequence ID No. 133, as well as other species homologs or orthologs. The hsa-miR-6780b-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6780b-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6780b" (miRBase Accession No. MI0022681, Sequence ID No. 409).

[0215] As used herein, the terms "hsa-miR-7845-5p gene" or "hsa-miR-7845-5p" include the hsa-miR-7845-5p gene (miRBase Accession No. MIMAT0030420) described in Sequence ID No. 134, as well as other species homologs or orthologs. The hsa-miR-7845-5p gene can be obtained by the method described by Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, "hsa-miR-7845-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-7845" (miRBase Accession No. MI0025515, Sequence ID No. 410).

[0216] As used herein, the terms "hsa-miR-6798-3p gene" or "hsa-miR-6798-3p" include the hsa-miR-6798-3p gene (miRBase Accession No. MIMAT0027497) described in Sequence ID No. 135, as well as other species homologs or orthologs. The hsa-miR-6798-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6798-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6798" (miRBase Accession No. MI0022643, Sequence ID No. 314).

[0217] As used herein, the terms "hsa-miR-665 gene" or "hsa-miR-665" include the hsa-miR-665 gene (miRBase Accession No. MIMAT0004952) described in Sequence ID No. 136, as well as other species homologs or orthologs. The hsa-miR-665 gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-665" is known to have a hairpin-like structure as its precursor, "hsa-mir-665" (miRBase Accession No. MI0005563, Sequence ID No. 411).

[0218] As used herein, the terms "hsa-miR-6848-5p gene" or "hsa-miR-6848-5p" include the hsa-miR-6848-5p gene (miRBase Accession No. MIMAT0027596) described in Sequence ID No. 137, as well as other species homologs or orthologs. The hsa-miR-6848-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6848-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6848" (miRBase Accession No. MI0022694, Sequence ID No. 412).

[0219] As used herein, the terms "hsa-miR-5008-5p gene" or "hsa-miR-5008-5p" include the hsa-miR-5008-5p gene (miRBase Accession No. MIMAT0021039) described in Sequence ID No. 138, as well as other species homologs or orthologs. The hsa-miR-5008-5p gene can be obtained by the method described by Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. In addition, "hsa-miR-5008-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-5008" (miRBase Accession No. MI0017876, Sequence ID No. 413).

[0220] As used herein, the terms "hsa-miR-4294 gene" or "hsa-miR-4294" include the hsa-miR-4294 gene (miRBase Accession No. MIMAT0016849) described in Sequence ID No. 139, as well as other species homologs or orthologs. The hsa-miR-4294 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4294" is known to have a hairpin-like structure as its precursor, "hsa-mir-4294" (miRBase Accession No. MI0015827, Sequence ID No. 414).

[0221] As used herein, the terms “hsa-miR-6511a-5p gene” or “hsa-miR-6511a-5p” include the hsa-miR-6511a-5p gene (miRBase Accession No. MIMAT0025478) described in Sequence ID No. 140, as well as other species homologs or orthologs. The hsa-miR-6511a-5p gene can be obtained by the method described by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. Furthermore, "hsa-miR-6511a-5p" is known to have hairpin-like precursors, "hsa-mir-6511a-1, hsa-mir-6511a-2, hsa-mir-6511a-3, hsa-mir-6511a-4" (miRBase Accession No. MI0022223, MI0023564, MI0023565, MI0023566, SEQ ID NOs. 415, 416, 417, 418).

[0222] As used herein, the terms "hsa-miR-4435 gene" or "hsa-miR-4435" include the hsa-miR-4435 gene described in Sequence ID No. 141 (miRBase Accession No. MIMAT0018951) and other species homologs or orthologs. The hsa-miR-4435 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4435" is known to have hairpin-like precursors, "hsa-mir-4435-1, hsa-mir-4435-2" (miRBase Accession No. MI0016775, MI0016777, Sequence ID No. 419, 420).

[0223] As used herein, the terms "hsa-miR-4747-3p gene" or "hsa-miR-4747-3p" include the hsa-miR-4747-3p gene (miRBase Accession No. MIMAT0019883) described in Sequence ID No. 142, as well as other species homologs or orthologs. The hsa-miR-4747-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4747-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4747" (miRBase Accession No. MI0017386, Sequence ID No. 421).

[0224] As used herein, the terms "hsa-miR-6880-3p gene" or "hsa-miR-6880-3p" include the hsa-miR-6880-3p gene (miRBase Accession No. MIMAT0027661) described in Sequence ID No. 143, as well as other species homologs or orthologs. The hsa-miR-6880-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6880-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6880" (miRBase Accession No. MI0022727, Sequence ID No. 422).

[0225] As used herein, the terms "hsa-miR-6869-5p gene" or "hsa-miR-6869-5p" include the hsa-miR-6869-5p gene (miRBase Accession No. MIMAT0027638) described in Sequence ID No. 144, as well as other species homologs or orthologs. The hsa-miR-6869-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6869-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6869" (miRBase Accession No. MI0022716, Sequence ID No. 423).

[0226] As used herein, the terms "hsa-miR-7150 gene" or "hsa-miR-7150" include the hsa-miR-7150 gene (miRBase Accession No. MIMAT0028211) described in Sequence ID No. 145, as well as other species homologs or orthologs. The hsa-miR-7150 gene can be obtained by the method described by Oulas A et al., 2009, Nucleic Acids Res, Vol. 37, pp. 3276-3287. In addition, "hsa-miR-7150" is known to have a hairpin-like structure as its precursor, "hsa-mir-7150" (miRBase Accession No. MI0023610, Sequence ID No. 424).

[0227] As used herein, the terms "hsa-miR-1260a gene" or "hsa-miR-1260a" include the hsa-miR-1260a gene (miRBase Accession No. MIMAT0005911) described in Sequence ID No. 146, as well as other species homologs or orthologs. The hsa-miR-1260a gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1260a" is known to have a hairpin-like structure as its precursor, "hsa-mir-1260a" (miRBase Accession No. MI0006394, Sequence ID No. 425).

[0228] As used herein, the terms "hsa-miR-6877-5p gene" or "hsa-miR-6877-5p" include the hsa-miR-6877-5p gene (miRBase Accession No. MIMAT0027654) described in Sequence ID No. 147, as well as other species homologs or orthologs. The hsa-miR-6877-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6877-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6877" (miRBase Accession No. MI0022724, Sequence ID No. 426).

[0229] As used herein, the terms "hsa-miR-6721-5p gene" or "hsa-miR-6721-5p" include the hsa-miR-6721-5p gene (miRBase Accession No. MIMAT0025852) described in Sequence ID No. 148, as well as other species homologs or orthologs. The hsa-miR-6721-5p gene can be obtained by the method described by Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, "hsa-miR-6721-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6721" (miRBase Accession No. MI0022556, Sequence ID No. 427).

[0230] As used herein, the terms "hsa-miR-4656 gene" or "hsa-miR-4656" include the hsa-miR-4656 gene (miRBase Accession No. MIMAT0019723) described in Sequence ID No. 149, as well as other species homologs or orthologs. The hsa-miR-4656 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4656" is known to have a hairpin-like structure as its precursor, "hsa-mir-4656" (miRBase Accession No. MI0017284, Sequence ID No. 428).

[0231] As used herein, the terms "hsa-miR-1229-5p gene" or "hsa-miR-1229-5p" include the hsa-miR-1229-5p gene (miRBase Accession No. MIMAT0022942) described in Sequence ID No. 150, as well as other species homologs or orthologs. The hsa-miR-1229-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1229-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1229" (miRBase Accession No. MI0006319, Sequence ID No. 429).

[0232] As used herein, the terms "hsa-miR-4433a-3p gene" or "hsa-miR-4433a-3p" include the hsa-miR-4433a-3p gene (miRBase Accession No. MIMAT0018949) described in Sequence ID No. 151, as well as other species homologs or orthologs. The hsa-miR-4433a-3p gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4433a-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4433a" (miRBase Accession No. MI0016773, Sequence ID No. 405).

[0233] As used herein, the terms "hsa-miR-4274 gene" or "hsa-miR-4274" include the hsa-miR-4274 gene (miRBase Accession No. MIMAT0016906) described in Sequence ID No. 152, as well as other species homologs or orthologs. The hsa-miR-4274 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4274" is known to have a hairpin-like structure as its precursor, "hsa-mir-4274" (miRBase Accession No. MI0015884, Sequence ID No. 430).

[0234] As used herein, the terms "hsa-miR-4419b gene" or "hsa-miR-4419b" include the hsa-miR-4419b gene (miRBase Accession No. MIMAT0019034) described in Sequence ID No. 153, as well as other species homologs or orthologs. The hsa-miR-4419b gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4419b" is known to have a hairpin-like structure as its precursor, "hsa-mir-4419b" (miRBase Accession No. MI0016861, Sequence ID No. 431).

[0235] As used herein, the terms "hsa-miR-4674 gene" or "hsa-miR-4674" include the hsa-miR-4674 gene (miRBase Accession No. MIMAT0019756) described in Sequence ID No. 154, as well as other species homologs or orthologs. The hsa-miR-4674 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4674" is known to have a hairpin-like structure as its precursor, "hsa-mir-4674" (miRBase Accession No. MI0017305, Sequence ID No. 432).

[0236] As used herein, the terms "hsa-miR-6893-5p gene" or "hsa-miR-6893-5p" include the hsa-miR-6893-5p gene (miRBase Accession No. MIMAT0027686) described in Sequence ID No. 155, as well as other species homologs or orthologs. The hsa-miR-6893-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6893-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6893" (miRBase Accession No. MI0022740, Sequence ID No. 433).

[0237] As used herein, the terms "hsa-miR-6763-3p gene" or "hsa-miR-6763-3p" include the hsa-miR-6763-3p gene (miRBase Accession No. MIMAT0027427) described in Sequence ID No. 156, as well as other species homologs or orthologs. The hsa-miR-6763-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6763-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6763" (miRBase Accession No. MI0022608, Sequence ID No. 434).

[0238] As used herein, the terms "hsa-miR-6762-5p gene" or "hsa-miR-6762-5p" include the hsa-miR-6762-5p gene (miRBase Accession No. MIMAT0027424) described in Sequence ID No. 157, as well as other species homologs or orthologs. The hsa-miR-6762-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6762-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6762" (miRBase Accession No. MI0022607, Sequence ID No. 435).

[0239] As used herein, the terms "hsa-miR-6738-5p gene" or "hsa-miR-6738-5p" include the hsa-miR-6738-5p gene (miRBase Accession No. MIMAT0027377) described in Sequence ID No. 158, as well as other species homologs or orthologs. The hsa-miR-6738-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6738-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6738" (miRBase Accession No. MI0022583, Sequence ID No. 436).

[0240] As used herein, the terms "hsa-miR-4513 gene" or "hsa-miR-4513" include the hsa-miR-4513 gene (miRBase Accession No. MIMAT0019050) described in Sequence ID No. 159, as well as other species homologs or orthologs. The hsa-miR-4513 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4513" is known to have a hairpin-like structure as its precursor, "hsa-mir-4513" (miRBase Accession No. MI0016879, Sequence ID No. 437).

[0241] As used herein, the terms "hsa-miR-6746-5p gene" or "hsa-miR-6746-5p" include the hsa-miR-6746-5p gene (miRBase Accession No. MIMAT0027392) described in Sequence ID No. 160, as well as other species homologs or orthologs. The hsa-miR-6746-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6746-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6746" (miRBase Accession No. MI0022591, Sequence ID No. 438).

[0242] As used herein, the terms "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" include the hsa-miR-6880-5p gene (miRBase Accession No. MIMAT0027660) described in Sequence ID No. 161, as well as other species homologs or orthologs. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6880-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6880" (miRBase Accession No. MI0022727, Sequence ID No. 422).

[0243] As used herein, the terms "hsa-miR-4736 gene" or "hsa-miR-4736" include the hsa-miR-4736 gene (miRBase Accession No. MIMAT0019862) described in Sequence ID No. 162, as well as other species homologs or orthologs. The hsa-miR-4736 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4736" is known to have a hairpin-like structure as its precursor, "hsa-mir-4736" (miRBase Accession No. MI0017373, Sequence ID No. 439).

[0244] As used herein, the terms "hsa-miR-718 gene" or "hsa-miR-718" include the hsa-miR-718 gene (miRBase Accession No. MIMAT0012735) described in Sequence ID No. 163, as well as other species homologs or orthologs. The hsa-miR-718 gene can be obtained by the method described by Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. In addition, "hsa-miR-718" is known to have a hairpin-like structure as its precursor, "hsa-mir-718" (miRBase Accession No. MI0012489, Sequence ID No. 440).

[0245] As used herein, the terms "hsa-miR-6717-5p gene" or "hsa-miR-6717-5p" include the hsa-miR-6717-5p gene (miRBase Accession No. MIMAT0025846) described in Sequence ID No. 164, as well as other species homologs or orthologs. The hsa-miR-6717-5p gene can be obtained by the method described by Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, "hsa-miR-6717-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6717" (miRBase Accession No. MI0022551, Sequence ID No. 441).

[0246] As used herein, the terms "hsa-miR-7847-3p gene" or "hsa-miR-7847-3p" include the hsa-miR-7847-3p gene (miRBase Accession No. MIMAT0030422) described in Sequence ID No. 165, as well as other species homologs or orthologs. The hsa-miR-7847-3p gene can be obtained by the method described by Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, "hsa-miR-7847-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-7847" (miRBase Accession No. MI0025517, Sequence ID No. 442).

[0247] As used herein, the terms "hsa-miR-760 gene" or "hsa-miR-760" include the hsa-miR-760 gene (miRBase Accession No. MIMAT0004957) described in Sequence ID No. 166, as well as other species homologs or orthologs. The hsa-miR-760 gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-760" is known to have a hairpin-like structure as its precursor, "hsa-mir-760" (miRBase Accession No. MI0005567, Sequence ID No. 443).

[0248] As used herein, the terms "hsa-miR-1199-5p gene" or "hsa-miR-1199-5p" include the hsa-miR-1199-5p gene (miRBase Accession No. MIMAT0031119) described in Sequence ID No. 167, as well as other species homologs or orthologs. The hsa-miR-1199-5p gene can be obtained by the method described by Salvi A et al., 2013, Int J Oncol, Vol. 42, pp. 391-402. In addition, "hsa-miR-1199" (miRBase Accession No. MI0020340, Sequence ID No. 444), which has a hairpin-like structure, is known as a precursor of "hsa-miR-1199-5p".

[0249] As used herein, the terms "hsa-miR-6813-5p gene" or "hsa-miR-6813-5p" include the hsa-miR-6813-5p gene (miRBase Accession No. MIMAT0027526) described in Sequence ID No. 168, as well as other species homologs or orthologs. The hsa-miR-6813-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6813-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6813" (miRBase Accession No. MI0022658, Sequence ID No. 445).

[0250] As used herein, the terms "hsa-miR-6769a-5p gene" or "hsa-miR-6769a-5p" include the hsa-miR-6769a-5p gene (miRBase Accession No. MIMAT0027438) described in Sequence ID No. 169, as well as other species homologs or orthologs. The hsa-miR-6769a-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6769a-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6769a" (miRBase Accession No. MI0022614, Sequence ID No. 446).

[0251] As used herein, the terms "hsa-miR-1193 gene" or "hsa-miR-1193" include the hsa-miR-1193 gene (miRBase Accession No. MIMAT0015049) described in Sequence ID No. 170, as well as other species homologs or orthologs. The hsa-miR-1193 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-1193" is known to have a hairpin-like structure as its precursor, "hsa-mir-1193" (miRBase Accession No. MI0014205, Sequence ID No. 447).

[0252] As used herein, the terms "hsa-miR-7108-3p gene" or "hsa-miR-7108-3p" include the hsa-miR-7108-3p gene (miRBase Accession No. MIMAT0028114) described in Sequence ID No. 171, as well as other species homologs or orthologs. The hsa-miR-7108-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-7108" (miRBase Accession No. MI0022959, Sequence ID No. 448), which has a hairpin-like structure, is known as a precursor of "hsa-miR-7108-3p".

[0253] As used herein, the terms "hsa-miR-6741-5p gene" or "hsa-miR-6741-5p" include the hsa-miR-6741-5p gene (miRBase Accession No. MIMAT0027383) described in Sequence ID No. 172, as well as other species homologs or orthologs. The hsa-miR-6741-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6741-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6741" (miRBase Accession No. MI0022586, Sequence ID No. 449).

[0254] As used herein, the terms "hsa-miR-4298 gene" or "hsa-miR-4298" include the hsa-miR-4298 gene (miRBase Accession No. MIMAT0016852) described in Sequence ID No. 173, as well as other species homologs or orthologs. The hsa-miR-4298 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4298" is known to have a hairpin-like structure as its precursor, "hsa-mir-4298" (miRBase Accession No. MI0015830, Sequence ID No. 450).

[0255] As used herein, the terms "hsa-miR-6796-3p gene" or "hsa-miR-6796-3p" include the hsa-miR-6796-3p gene (miRBase Accession No. MIMAT0027493) described in Sequence ID No. 174, as well as other species homologs or orthologs. The hsa-miR-6796-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6796-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6796" (miRBase Accession No. MI0022641, Sequence ID No. 451).

[0256] As used herein, the terms "hsa-miR-4750-5p gene" or "hsa-miR-4750-5p" include the hsa-miR-4750-5p gene (miRBase Accession No. MIMAT0019887) described in Sequence ID No. 175, as well as other species homologs or orthologs. The hsa-miR-4750-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4750-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4750" (miRBase Accession No. MI0017389, Sequence ID No. 452).

[0257] As used herein, the terms "hsa-miR-6785-5p gene" or "hsa-miR-6785-5p" include the hsa-miR-6785-5p gene (miRBase Accession No. MIMAT0027470) described in Sequence ID No. 176, as well as other species homologs or orthologs. The hsa-miR-6785-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6785-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6785" (miRBase Accession No. MI0022630, Sequence ID No. 453).

[0258] As used herein, the terms "hsa-miR-1292-3p gene" or "hsa-miR-1292-3p" include the hsa-miR-1292-3p gene (miRBase Accession No. MIMAT0022948) described in Sequence ID No. 177, as well as other species homologs or orthologs. The hsa-miR-1292-3p gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1292-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1292" (miRBase Accession No. MI0006433, Sequence ID No. 454).

[0259] As used herein, the terms "hsa-miR-4749-3p gene" or "hsa-miR-4749-3p" include the hsa-miR-4749-3p gene (miRBase Accession No. MIMAT0019886) described in Sequence ID No. 178, as well as other species homologs or orthologs. The hsa-miR-4749-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4749-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4749" (miRBase Accession No. MI0017388, Sequence ID No. 455).

[0260] As used herein, the terms "hsa-miR-6800-3p gene" or "hsa-miR-6800-3p" include the hsa-miR-6800-3p gene (miRBase Accession No. MIMAT0027501) described in Sequence ID No. 179, as well as other species homologs or orthologs. The hsa-miR-6800-3p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6800-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6800" (miRBase Accession No. MI0022645, Sequence ID No. 293).

[0261] As used herein, the terms "hsa-miR-4722-5p gene" or "hsa-miR-4722-5p" include the hsa-miR-4722-5p gene (miRBase Accession No. MIMAT0019836) described in Sequence ID No. 180, as well as other species homologs or orthologs. The hsa-miR-4722-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4722-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4722" (miRBase Accession No. MI0017357, Sequence ID No. 456).

[0262] As used herein, the terms "hsa-miR-4746-3p gene" or "hsa-miR-4746-3p" include the hsa-miR-4746-3p gene (miRBase Accession No. MIMAT0019881) described in Sequence ID No. 181, as well as other species homologs or orthologs. The hsa-miR-4746-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4746-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4746" (miRBase Accession No. MI0017385, Sequence ID No. 457).

[0263] As used herein, the terms "hsa-miR-4450 gene" or "hsa-miR-4450" include the hsa-miR-4450 gene (miRBase Accession No. MIMAT0018971) described in Sequence ID No. 182, as well as other species homologs or orthologs. The hsa-miR-4450 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4450" is known to have a hairpin-like structure as its precursor, "hsa-mir-4450" (miRBase Accession No. MI0016795, Sequence ID No. 458).

[0264] As used herein, the terms "hsa-miR-6795-5p gene" or "hsa-miR-6795-5p" include the hsa-miR-6795-5p gene (miRBase Accession No. MIMAT0027490) described in Sequence ID No. 183, as well as other species homologs or orthologs. The hsa-miR-6795-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6795-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6795" (miRBase Accession No. MI0022640, Sequence ID No. 459).

[0265] The terms "hsa-miR-365a-5p gene" or "hsa-miR-365a-5p" as used herein include the hsa-miR-365a-5p gene (miRBase Accession No. MIMAT0009199) described in Sequence ID No. 184, as well as other species homologs or orthologs. The hsa-miR-365a-5p gene can be obtained by the method described by Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. In addition, "hsa-miR-365a" is known to have a hairpin-like structure as its precursor, "hsa-mir-365a" (miRBase Accession No. MI0000767, Sequence ID No. 460).

[0266] As used herein, the terms "hsa-miR-498 gene" or "hsa-miR-498" include the hsa-miR-498 gene (miRBase Accession No. MIMAT0002824) described in Sequence ID No. 185, as well as other species homologs or orthologs. The hsa-miR-498 gene can be obtained by the method described by Bentwich I et al., 2005, Nat Genet, Vol. 37, pp. 766-770. In addition, "hsa-miR-498" is known to have a hairpin-like structure as its precursor, "hsa-mir-498" (miRBase Accession No. MI0003142, Sequence ID No. 461).

[0267] The terms "hsa-miR-6797-5p gene" or "hsa-miR-6797-5p" as used herein include the hsa-miR-6797-5p gene (miRBase Accession No. MIMAT0027494) described in Sequence ID No. 186, as well as other species homologs or orthologs. The hsa-miR-6797-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6797-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6797" (miRBase Accession No. MI0022642, Sequence ID No. 462).

[0268] As used herein, the terms "hsa-miR-1470 gene" or "hsa-miR-1470" include the hsa-miR-1470 gene (miRBase Accession No. MIMAT0007348) described in Sequence ID No. 187, as well as other species homologs or orthologs. The hsa-miR-1470 gene can be obtained by the method described by Kawaji H et al., 2008, BMC Genomics, Vol. 9, p. 157. In addition, "hsa-miR-1470" is known to have a hairpin-like structure as its precursor, "hsa-mir-1470" (miRBase Accession No. MI0007075, Sequence ID No. 463).

[0269] As used herein, the terms "hsa-miR-6851-5p gene" or "hsa-miR-6851-5p" include the hsa-miR-6851-5p gene (miRBase Accession No. MIMAT0027602) described in Sequence ID No. 188, as well as other species homologs or orthologs. The hsa-miR-6851-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6851-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6851" (miRBase Accession No. MI0022697, Sequence ID No. 464).

[0270] As used herein, the terms "hsa-miR-1247-3p gene" or "hsa-miR-1247-3p" include the hsa-miR-1247-3p gene (miRBase Accession No. MIMAT0022721) described in Sequence ID No. 189, as well as other species homologs or orthologs. The hsa-miR-1247-3p gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1247-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1247" (miRBase Accession No. MI0006382, Sequence ID No. 465).

[0271] As used herein, the terms "hsa-miR-5196-5p gene" or "hsa-miR-5196-5p" include the hsa-miR-5196-5p gene (miRBase Accession No. MIMAT0021128) described in Sequence ID No. 190, as well as other species homologs or orthologs. The hsa-miR-5196-5p gene can be obtained by the method described by Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. In addition, "hsa-miR-5196-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-5196" (miRBase Accession No. MI0018175, Sequence ID No. 466).

[0272] As used herein, the terms "hsa-miR-208a-5p gene" or "hsa-miR-208a-5p" include the hsa-miR-208a-5p gene (miRBase Accession No. MIMAT0026474) described in Sequence ID No. 191, as well as other species homologs or orthologs. The hsa-miR-208a-5p gene can be obtained by the method described by Lagos-Quintana M et al., 2003, RNA, Vol. 9, pp. 175-179. In addition, "hsa-miR-208a-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-208a" (miRBase Accession No. MI0000251, Sequence ID No. 467).

[0273] As used herein, the term "hsa-miR-6842-5p gene" or "hsa-miR-6842-5p" includes the hsa-miR-6842-5p gene set forth in SEQ ID NO: 192 (miRBase Accession No. MIMAT0027586), as well as homologs or orthologs from other species. The hsa-miR-6842-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, p. 1634-1645. Further, "hsa-mir-6842" (miRBase Accession No. MI0022688, SEQ ID NO: 468), which adopts a hairpin-like structure, is known as the precursor of "hsa-miR-6842-5p".

[0274] As used herein, the term "hsa-miR-150-3p gene" or "hsa-miR-150-3p" includes the hsa-miR-150-3p gene set forth in SEQ ID NO: 193 (miRBase Accession No. MIMAT0004610), as well as homologs or orthologs from other species. The hsa-miR-150-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, p. 735-739. Further, "hsa-mir-150" (miRBase Accession No. MI0000479, SEQ ID NO: 469), which adopts a hairpin-like structure, is known as the precursor of "hsa-miR-150-3p".

[0275] As used herein, the term "hsa-miR-4534 gene" or "hsa-miR-4534" includes the hsa-miR-4534 gene set forth in SEQ ID NO: 194 (miRBase Accession No. MIMAT0019073), as well as homologs or orthologs from other species. The hsa-miR-4534 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4534" is known to have "hsa-mir-4534" (miRBase Accession No. MI0016901, SEQ ID NO: 470), which adopts a hairpin-like structure as its precursor.

[0276] As used herein, the term "hsa-miR-3135b gene" or "hsa-miR-3135b" includes the hsa-miR-3135b gene set forth in SEQ ID NO: 195 (miRBase Accession No. MIMAT0018985), as well as homologs or orthologs from other species. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-3135b" is known to have "hsa-mir-3135b" (miRBase Accession No. MI0016809, SEQ ID NO: 471), which adopts a hairpin-like structure as its precursor.

[0277] As used herein, the terms "hsa-miR-3131 gene" or "hsa-miR-3131" include the hsa-miR-3131 gene (miRBase Accession No. MIMAT0014996) described in Sequence ID No. 196, as well as other species homologs or orthologs. The hsa-miR-3131 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3131" is known to have a hairpin-like structure as its precursor, "hsa-mir-3131" (miRBase Accession No. MI0014151, Sequence ID No. 472).

[0278] As used herein, the terms "hsa-miR-4792 gene" or "hsa-miR-4792" include the hsa-miR-4792 gene (miRBase Accession No. MIMAT0019964) described in Sequence ID No. 197, as well as other species homologs or orthologs. The hsa-miR-4792 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4792" is known to have a hairpin-like structure as its precursor, "hsa-mir-4792" (miRBase Accession No. MI0017439, Sequence ID No. 473).

[0279] As used herein, the terms "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" include the hsa-miR-6510-5p gene (miRBase Accession No. MIMAT0025476) described in Sequence ID No. 198, as well as other species homologs or orthologs. The hsa-miR-6510-5p gene can be obtained by the method described by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. In addition, "hsa-miR-6510-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6510" (miRBase Accession No. MI0022222, Sequence ID No. 474).

[0280] As used herein, the terms "hsa-miR-504-3p gene" or "hsa-miR-504-3p" include the hsa-miR-504-3p gene (miRBase Accession No. MIMAT0026612) described in Sequence ID No. 199, as well as other species homologs or orthologs. The hsa-miR-504-3p gene can be obtained by the method described by Bentwich I et al., 2005, Nat Genet, Vol. 37, pp. 766-770. In addition, "hsa-miR-504-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-504" (miRBase Accession No. MI0003189, Sequence ID No. 475).

[0281] As used herein, the terms "hsa-miR-3619-3p gene" or "hsa-miR-3619-3p" include the hsa-miR-3619-3p gene (miRBase Accession No. MIMAT0019219) described in Sequence ID No. 200, as well as other species homologs or orthologs. The hsa-miR-3619-3p gene can be obtained by the method described by Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, "hsa-miR-3619-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3619" (miRBase Accession No. MI0016009, Sequence ID No. 476).

[0282] As used herein, the terms "hsa-miR-671-5p gene" or "hsa-miR-671-5p" include the hsa-miR-671-5p gene (miRBase Accession No. MIMAT0003880) described in Sequence ID No. 201, as well as other species homologs or orthologs. The hsa-miR-671-5p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-671-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-671" (miRBase Accession No. MI0003760, Sequence ID No. 477).

[0283] As used herein, the terms "hsa-miR-4667-5p gene" or "hsa-miR-4667-5p" include the hsa-miR-4667-5p gene (miRBase Accession No. MIMAT0019743) described in Sequence ID No. 202, as well as other species homologs or orthologs. The hsa-miR-4667-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4667-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4667" (miRBase Accession No. MI0017297, Sequence ID No. 478).

[0284] As used herein, the terms "hsa-miR-4430 gene" or "hsa-miR-4430" include the hsa-miR-4430 gene (miRBase Accession No. MIMAT0018945) described in Sequence ID No. 203, as well as other species homologs or orthologs. The hsa-miR-4430 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4430" is known to have a hairpin-like structure as its precursor, "hsa-mir-4430" (miRBase Accession No. MI0016769, Sequence ID No. 479).

[0285] As used herein, the terms "hsa-miR-3195 gene" or "hsa-miR-3195" include the hsa-miR-3195 gene (miRBase Accession No. MIMAT0015079) described in Sequence ID No. 204, as well as other species homologs or orthologs. The hsa-miR-3195 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3195" is known to have a hairpin-like structure as its precursor, "hsa-mir-3195" (miRBase Accession No. MI0014240, Sequence ID No. 480).

[0286] As used herein, the terms "hsa-miR-3679-5p gene" or "hsa-miR-3679-5p" include the hsa-miR-3679-5p gene (miRBase Accession No. MIMAT0018104) described in Sequence ID No. 205, as well as other species homologs or orthologs. The hsa-miR-3679-5p gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3679-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3679" (miRBase Accession No. MI0016080, Sequence ID No. 358).

[0287] As used herein, the terms "hsa-miR-6076 gene" or "hsa-miR-6076" include the hsa-miR-6076 gene (miRBase Accession No. MIMAT0023701) described in Sequence ID No. 206, as well as other species homologs or orthologs. The hsa-miR-6076 gene can be obtained by the method described by Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. In addition, "hsa-miR-6076" is known to have a hairpin-like structure as its precursor, "hsa-mir-6076" (miRBase Accession No. MI0020353, Sequence ID No. 481).

[0288] As used herein, the terms "hsa-miR-6515-5p gene" or "hsa-miR-6515-5p" include the hsa-miR-6515-5p gene (miRBase Accession No. MIMAT0025486) described in Sequence ID No. 207, as well as other species homologs or orthologs. The hsa-miR-6515-5p gene can be obtained by the method described by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. In addition, "hsa-miR-6515-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6515" (miRBase Accession No. MI0022227, Sequence ID No. 340).

[0289] As used herein, the terms "hsa-miR-6820-5p gene" or "hsa-miR-6820-5p" include the hsa-miR-6820-5p gene (miRBase Accession No. MIMAT0027540) described in Sequence ID No. 208, as well as other species homologs or orthologs. The hsa-miR-6820-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6820-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6820" (miRBase Accession No. MI0022665, Sequence ID No. 482).

[0290] As used herein, the terms "hsa-miR-4634 gene" or "hsa-miR-4634" include the hsa-miR-4634 gene (miRBase Accession No. MIMAT0019691) described in Sequence ID No. 209, as well as other species homologs or orthologs. The hsa-miR-4634 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4634" is known to have a hairpin-like structure as its precursor, "hsa-mir-4634" (miRBase Accession No. MI0017261, Sequence ID No. 483).

[0291] As used herein, the terms "hsa-miR-187-5p gene" or "hsa-miR-187-5p" include the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) described in Sequence ID No. 210, as well as other species homologs or orthologs. The hsa-miR-187-5p gene can be obtained by the method described by Lim LP et al., 2003, Science, Vol. 299, p. 1540. In addition, "hsa-miR-187-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-187" (miRBase Accession No. MI0000274, Sequence ID No. 484).

[0292] As used herein, the terms "hsa-miR-6763-5p gene" or "hsa-miR-6763-5p" include the hsa-miR-6763-5p gene (miRBase Accession No. MIMAT0027426) described in Sequence ID No. 211, as well as other species homologs or orthologs. The hsa-miR-6763-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6763-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6763" (miRBase Accession No. MI0022608, Sequence ID No. 434).

[0293] As used herein, the terms "hsa-miR-1908-3p gene" or "hsa-miR-1908-3p" include the hsa-miR-1908-3p gene (miRBase Accession No. MIMAT0026916) described in Sequence ID No. 212, as well as other species homologs or orthologs. The hsa-miR-1908-3p gene can be obtained by the method described by Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, "hsa-miR-1908-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1908" (miRBase Accession No. MI0008329, Sequence ID No. 393).

[0294] As used herein, the terms "hsa-miR-1181 gene" or "hsa-miR-1181" include the hsa-miR-1181 gene (miRBase Accession No. MIMAT0005826) described in Sequence ID No. 213, as well as other species homologs or orthologs. The hsa-miR-1181 gene can be obtained by the method described by Subramanian S et al., 2008, Oncogene, Vol. 27, pp. 2015-2026. In addition, "hsa-miR-1181" is known to have a hairpin-like structure as its precursor, "hsa-mir-1181" (miRBase Accession No. MI0006274, Sequence ID No. 485).

[0295] As used herein, the term "hsa-miR-6782-5p gene" or "hsa-miR-6782-5p" includes the hsa-miR-6782-5p gene set forth in SEQ ID NO: 214 (miRBase Accession No. MIMAT0027464), as well as homologs or orthologs from other species. The hsa-miR-6782-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, p. 1634-1645. Furthermore, "hsa-mir-6782" (miRBase Accession No. MI0022627, SEQ ID NO: 486), which adopts a hairpin-like structure, is known as the precursor of "hsa-miR-6782-5p".

[0296] As used herein, the term "hsa-miR-5010-5p gene" or "hsa-miR-5010-5p" includes the hsa-miR-5010-5p gene set forth in SEQ ID NO: 215 (miRBase Accession No. MIMAT0021043), as well as homologs or orthologs from other species. The hsa-miR-5010-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, vol. 8, p. 378-383. Furthermore, "hsa-mir-5010" (miRBase Accession No. MI0017878, SEQ ID NO: 487), which adopts a hairpin-like structure, is known as the precursor of "hsa-miR-5010-5p".

[0297] As used herein, the terms "hsa-miR-6870-5p gene" or "hsa-miR-6870-5p" include the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) described in Sequence ID No. 216, as well as other species homologs or orthologs. The hsa-miR-6870-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6870-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6870" (miRBase Accession No. MI0022717, Sequence ID No. 488).

[0298] As used herein, the terms "hsa-miR-6124 gene" or "hsa-miR-6124" include the hsa-miR-6124 gene (miRBase Accession No. MIMAT0024597) described in Sequence ID No. 217, as well as other species homologs or orthologs. The hsa-miR-6124 gene can be obtained by the method described by Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. In addition, "hsa-miR-6124" is known to have a hairpin-like structure as its precursor, "hsa-mir-6124" (miRBase Accession No. MI0021258, Sequence ID No. 489).

[0299] As used herein, the terms "hsa-miR-1249-5p gene" or "hsa-miR-1249-5p" include the hsa-miR-1249-5p gene (miRBase Accession No. MIMAT0032029) described in Sequence ID No. 218, as well as other species homologs or orthologs. The hsa-miR-1249-5p gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1249-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1249" (miRBase Accession No. MI0006384, Sequence ID No. 321).

[0300] As used herein, the terms "hsa-miR-6511b-5p gene" or "hsa-miR-6511b-5p" include the hsa-miR-6511b-5p gene (miRBase Accession No. MIMAT0025847) described in Sequence ID No. 219, as well as other species homologs or orthologs. The hsa-miR-6511b-5p gene can be obtained by the method described by Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, "hsa-miR-6511b-1, hsa-mir-6511b-2" (miRBase Accession No. MI0022552, MI0023431, Sequence ID No. 490, 491), which have a hairpin-like structure, are known as precursors of "hsa-miR-6511b-5p".

[0301] As used herein, the terms "hsa-miR-1254 gene" or "hsa-miR-1254" include the hsa-miR-1254 gene (miRBase Accession No. MIMAT0005905) described in Sequence ID No. 220, as well as other species homologs or orthologs. The hsa-miR-1254 gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1254" is known to have hairpin-like precursors, "hsa-mir-1254-1, hsa-mir-1254-2" (miRBase Accession No. MI0006388, MI0016747, Sequence ID No. 492, 493).

[0302] As used herein, the terms "hsa-miR-4727-3p gene" or "hsa-miR-4727-3p" include the hsa-miR-4727-3p gene (miRBase Accession No. MIMAT0019848) described in Sequence ID No. 221, as well as other species homologs or orthologs. The hsa-miR-4727-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4727-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4727" (miRBase Accession No. MI0017364, Sequence ID No. 494).

[0303] As used herein, the terms "hsa-miR-4259 gene" or "hsa-miR-4259" include the hsa-miR-4259 gene (miRBase Accession No. MIMAT0016880) described in Sequence ID No. 222, as well as other species homologs or orthologs. The hsa-miR-4259 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4259" is known to have a hairpin-like structure as its precursor, "hsa-mir-4259" (miRBase Accession No. MI0015858, Sequence ID No. 495).

[0304] As used herein, the terms "hsa-miR-4771 gene" or "hsa-miR-4771" include the hsa-miR-4771 gene (miRBase Accession No. MIMAT0019925) described in Sequence ID No. 223, as well as other species homologs or orthologs. The hsa-miR-4771 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4771" is known to have hairpin-like structures as its precursors, "hsa-mir-4771-1, hsa-mir-4771-2" (miRBase Accession No. MI0017412, MI0017413, Sequence ID No. 496, 497).

[0305] As used herein, the terms "hsa-miR-3622a-5p gene" or "hsa-miR-3622a-5p" include the hsa-miR-3622a-5p gene (miRBase Accession No. MIMAT0018003) described in Sequence ID No. 224, as well as other species homologs or orthologs. The hsa-miR-3622a-5p gene can be obtained by the method described by Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, "hsa-miR-3622a-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3622a" (miRBase Accession No. MI0016013, Sequence ID No. 498).

[0306] As used herein, the terms "hsa-miR-4480 gene" or "hsa-miR-4480" include the hsa-miR-4480 gene (miRBase Accession No. MIMAT0019014) described in Sequence ID No. 225, as well as other species homologs or orthologs. The hsa-miR-4480 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4480" is known to have a hairpin-like structure as its precursor, "hsa-mir-4480" (miRBase Accession No. MI0016841, Sequence ID No. 499).

[0307] As used herein, the terms "hsa-miR-4740-5p gene" or "hsa-miR-4740-5p" include the hsa-miR-4740-5p gene (miRBase Accession No. MIMAT0019869) described in Sequence ID No. 226, as well as other species homologs or orthologs. The hsa-miR-4740-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4740-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4740" (miRBase Accession No. MI0017378, Sequence ID No. 500).

[0308] The terms "hsa-miR-6777-5p gene" or "hsa-miR-6777-5p" as used herein include the hsa-miR-6777-5p gene (miRBase Accession No. MIMAT0027454) described in Sequence ID No. 227, as well as other species homologs or orthologs. The hsa-miR-6777-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6777-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6777" (miRBase Accession No. MI0022622, Sequence ID No. 501).

[0309] As used herein, the terms "hsa-miR-6794-5p gene" or "hsa-miR-6794-5p" include the hsa-miR-6794-5p gene (miRBase Accession No. MIMAT0027488) described in Sequence ID No. 228, as well as other species homologs or orthologs. The hsa-miR-6794-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6794-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6794" (miRBase Accession No. MI0022639, Sequence ID No. 502).

[0310] As used herein, the terms "hsa-miR-4687-3p gene" or "hsa-miR-4687-3p" include the hsa-miR-4687-3p gene (miRBase Accession No. MIMAT0019775) described in Sequence ID No. 229, as well as other species homologs or orthologs. The hsa-miR-4687-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4687-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4687" (miRBase Accession No. MI0017319, Sequence ID No. 341).

[0311] As used herein, the terms "hsa-miR-6743-5p gene" or "hsa-miR-6743-5p" include the hsa-miR-6743-5p gene (miRBase Accession No. MIMAT0027387) described in Sequence ID No. 230, as well as other species homologs or orthologs. The hsa-miR-6743-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6743-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6743" (miRBase Accession No. MI0022588, Sequence ID No. 503).

[0312] The terms "hsa-miR-6771-5p gene" or "hsa-miR-6771-5p" as used herein include the hsa-miR-6771-5p gene (miRBase Accession No. MIMAT0027442) described in Sequence ID No. 231, as well as other species homologs or orthologs. The hsa-miR-6771-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6771-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6771" (miRBase Accession No. MI0022616, Sequence ID No. 504).

[0313] As used herein, the terms "hsa-miR-3141 gene" or "hsa-miR-3141" include the hsa-miR-3141 gene (miRBase Accession No. MIMAT0015010) described in Sequence ID No. 232, as well as other species homologs or orthologs. The hsa-miR-3141 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3141" is known to have a hairpin-like structure as its precursor, "hsa-mir-3141" (miRBase Accession No. MI0014165, Sequence ID No. 505).

[0314] As used herein, the terms "hsa-miR-3162-5p gene" or "hsa-miR-3162-5p" include the hsa-miR-3162-5p gene (miRBase Accession No. MIMAT0015036) described in Sequence ID No. 233, as well as other species homologs or orthologs. The hsa-miR-3162-5p gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3162-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-3162" (miRBase Accession No. MI0014192, Sequence ID No. 506).

[0315] As used herein, the terms "hsa-miR-4271 gene" or "hsa-miR-4271" include the hsa-miR-4271 gene (miRBase Accession No. MIMAT0016901) described in Sequence ID No. 234, as well as other species homologs or orthologs. The hsa-miR-4271 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4271" is known to have a hairpin-like structure as its precursor, "hsa-mir-4271" (miRBase Accession No. MI0015879, Sequence ID No. 507).

[0316] As used herein, the terms "hsa-miR-1227-5p gene" or "hsa-miR-1227-5p" include the hsa-miR-1227-5p gene (miRBase Accession No. MIMAT0022941) described in Sequence ID No. 235, as well as other species homologs or orthologs. The hsa-miR-1227-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, "hsa-miR-1227-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-1227" (miRBase Accession No. MI0006316, Sequence ID No. 508).

[0317] As used herein, the terms "hsa-miR-4257 gene" or "hsa-miR-4257" include the hsa-miR-4257 gene (miRBase Accession No. MIMAT0016878) described in Sequence ID No. 236, as well as other species homologs or orthologs. The hsa-miR-4257 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4257" is known to have a hairpin-like structure as its precursor, "hsa-mir-4257" (miRBase Accession No. MI0015856, Sequence ID No. 509).

[0318] As used herein, the terms "hsa-miR-4270 gene" or "hsa-miR-4270" include the hsa-miR-4270 gene (miRBase Accession No. MIMAT0016900) described in Sequence ID No. 237, as well as other species homologs or orthologs. The hsa-miR-4270 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4270" is known to have a hairpin-like structure as its precursor, "hsa-mir-4270" (miRBase Accession No. MI0015878, Sequence ID No. 510).

[0319] As used herein, the terms "hsa-miR-4516 gene" or "hsa-miR-4516" include the hsa-miR-4516 gene (miRBase Accession No. MIMAT0019053) described in Sequence ID No. 238, as well as other species homologs or orthologs. The hsa-miR-4516 gene can be obtained by the method described by Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4516" is known to have a hairpin-like structure as its precursor, "hsa-mir-4516" (miRBase Accession No. MI0016882, Sequence ID No. 511).

[0320] As used herein, the terms "hsa-miR-4651 gene" or "hsa-miR-4651" include the hsa-miR-4651 gene (miRBase Accession No. MIMAT0019715) described in Sequence ID No. 239, as well as other species homologs or orthologs. The hsa-miR-4651 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4651" is known to have a hairpin-like structure as its precursor, "hsa-mir-4651" (miRBase Accession No. MI0017279, Sequence ID No. 512).

[0321] As used herein, the terms "hsa-miR-4725-3p gene" or "hsa-miR-4725-3p" include the hsa-miR-4725-3p gene (miRBase Accession No. MIMAT0019844) described in Sequence ID No. 240, as well as other species homologs or orthologs. The hsa-miR-4725-3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4725-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-4725" (miRBase Accession No. MI0017362, Sequence ID No. 513).

[0322] As used herein, the terms "hsa-miR-6125 gene" or "hsa-miR-6125" include the hsa-miR-6125 gene (miRBase Accession No. MIMAT0024598) described in Sequence ID No. 241, as well as other species homologs or orthologs. The hsa-miR-6125 gene can be obtained by the method described by Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. In addition, "hsa-miR-6125" is known to have a hairpin-like structure as its precursor, "hsa-mir-6125" (miRBase Accession No. MI0021259, Sequence ID No. 514).

[0323] As used herein, the terms "hsa-miR-6732-5p gene" or "hsa-miR-6732-5p" include the hsa-miR-6732-5p gene (miRBase Accession No. MIMAT0027365) described in Sequence ID No. 242, as well as other species homologs or orthologs. The hsa-miR-6732-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6732-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6732" (miRBase Accession No. MI0022577, Sequence ID No. 515).

[0324] As used herein, the terms "hsa-miR-6791-5p gene" or "hsa-miR-6791-5p" include the hsa-miR-6791-5p gene (miRBase Accession No. MIMAT0027482) described in Sequence ID No. 243, as well as other species homologs or orthologs. The hsa-miR-6791-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6791-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6791" (miRBase Accession No. MI0022636, Sequence ID No. 516).

[0325] As used herein, the terms "hsa-miR-6819-5p gene" or "hsa-miR-6819-5p" include the hsa-miR-6819-5p gene (miRBase Accession No. MIMAT0027538) described in Sequence ID No. 244, as well as other species homologs or orthologs. The hsa-miR-6819-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6819-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6819" (miRBase Accession No. MI0022664, Sequence ID No. 517).

[0326] As used herein, the terms "hsa-miR-6891-5p gene" or "hsa-miR-6891-5p" include the hsa-miR-6891-5p gene (miRBase Accession No. MIMAT0027682) described in Sequence ID No. 245, as well as other species homologs or orthologs. The hsa-miR-6891-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-6891-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-6891" (miRBase Accession No. MI0022738, Sequence ID No. 518).

[0327] As used herein, the terms "hsa-miR-7108-5p gene" or "hsa-miR-7108-5p" include the hsa-miR-7108-5p gene (miRBase Accession No. MIMAT0028113) described in Sequence ID No. 246, as well as other species homologs or orthologs. The hsa-miR-7108-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-7108" (miRBase Accession No. MI0022959, Sequence ID No. 448), which has a hairpin-like structure, is known as a precursor of "hsa-miR-7108-5p".

[0328] As used herein, the terms "hsa-miR-7109-5p gene" or "hsa-miR-7109-5p" include the hsa-miR-7109-5p gene (miRBase Accession No. MIMAT0028115) described in Sequence ID No. 247, as well as other species homologs or orthologs. The hsa-miR-7109-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, "hsa-miR-7109" is known to have a hairpin-like structure as its precursor, "hsa-mir-7109" (miRBase Accession No. MI0022960, Sequence ID No. 519).

[0329] As used herein, the terms "hsa-miR-320a gene" or "hsa-miR-320a" include the hsa-miR-320a gene (miRBase Accession No. MIMAT0000510) described in Sequence ID No. 248, as well as other species homologs or orthologs. The hsa-miR-320a gene can be obtained by the method described by Michael MZ et al., 2003, Mol Cancer Res, Vol. 1, pp. 882-891. In addition, "hsa-miR-320a" is known to have a hairpin-like structure as its precursor, "hsa-mir-320a" (miRBase Accession No. MI0000542, Sequence ID No. 520).

[0330] As used herein, the terms "hsa-miR-663a gene" or "hsa-miR-663a" include the hsa-miR-663a gene (miRBase Accession No. MIMAT0003326) described in Sequence ID No. 249, as well as other species homologs or orthologs. The hsa-miR-663a gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-663a" is known to have a hairpin-like structure as its precursor, "hsa-mir-663a" (miRBase Accession No. MI0003672, Sequence ID No. 521).

[0331] As used herein, the terms "hsa-miR-328-5p gene" or "hsa-miR-328-5p" include the hsa-miR-328-5p gene (miRBase Accession No. MIMAT0026486) described in Sequence ID No. 250, as well as other species homologs or orthologs. The hsa-miR-328-5p gene can be obtained by the method described by Kim J et al., 2004, Proc Natl Acad Sci USA, Vol. 101, pp. 360-365. In addition, "hsa-miR-328-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-328" (miRBase Accession No. MI0000804, Sequence ID No. 522).

[0332] As used herein, the terms "hsa-miR-642b-3p gene" or "hsa-miR-642b-3p" include the hsa-miR-642b-3p gene (miRBase Accession No. MIMAT0018444) described in Sequence ID No. 251, as well as other species homologs or orthologs. The hsa-miR-642b-3p gene can be obtained by the method described by Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, "hsa-miR-642b-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-642b" (miRBase Accession No. MI0016685, Sequence ID No. 523).

[0333] As used herein, the terms "hsa-miR-128-2-5p gene" or "hsa-miR-128-2-5p" include the hsa-miR-128-2-5p gene (miRBase Accession No. MIMAT0031095) described in Sequence ID No. 252, as well as other species homologs or orthologs. The hsa-miR-128-2-5p gene can be obtained by the method described by Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, "hsa-miR-128-2-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-128-2" (miRBase Accession No. MI0000727, Sequence ID No. 524).

[0334] As used herein, the terms "hsa-miR-125a-3p gene" or "hsa-miR-125a-3p" include the hsa-miR-125a-3p gene (miRBase Accession No. MIMAT0004602) described in Sequence ID No. 253, as well as other species homologs or orthologs. The hsa-miR-125a-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, "hsa-miR-125a-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-125a" (miRBase Accession No. MI0000469, Sequence ID No. 525).

[0335] As used herein, the terms "hsa-miR-191-5p gene" or "hsa-miR-191-5p" include the hsa-miR-191-5p gene (miRBase Accession No. MIMAT0000440) described in SEQ ID NO. 254, as well as other species homologs or orthologs. The hsa-miR-191-5p gene can be obtained by the method described by Lagos-Quintana M et al., 2003, RNA, Vol. 9, pp. 175-179. In addition, "hsa-miR-191-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-191" (miRBase Accession No. MI0000465, SEQ ID NO. 526).

[0336] As used herein, the terms "hsa-miR-92b-5p gene" or "hsa-miR-92b-5p" include the hsa-miR-92b-5p gene (miRBase Accession No. MIMAT0004792) described in Sequence ID No. 255, as well as other species homologs or orthologs. The hsa-miR-92b-5p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-92b-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-92b" (miRBase Accession No. MI0003560, Sequence ID No. 527).

[0337] As used herein, the terms "hsa-miR-296-5p gene" or "hsa-miR-296-5p" include the hsa-miR-296-5p gene (miRBase Accession No. MIMAT0000690) described in Sequence ID No. 256, as well as other species homologs or orthologs. The hsa-miR-296-5p gene can be obtained by the method described by Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358. In addition, "hsa-miR-296-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-296" (miRBase Accession No. MI0000747, Sequence ID No. 336).

[0338] As used herein, the terms "hsa-miR-1246 gene" or "hsa-miR-1246" include the hsa-miR-1246 gene (miRBase Accession No. MIMAT0005898) described in Sequence ID No. 257, as well as other species homologs or orthologs. The hsa-miR-1246 gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1246" is known to have a hairpin-like structure as its precursor, "hsa-mir-1246" (miRBase Accession No. MI0006381, Sequence ID No. 528).

[0339] As used herein, the terms "hsa-miR-92a-2-5p gene" or "hsa-miR-92a-2-5p" include the hsa-miR-92a-2-5p gene (miRBase Accession No. MIMAT0004508) described in Sequence ID No. 258, as well as other species homologs or orthologs. The hsa-miR-92a-2-5p gene can be obtained by the method described by Mourelatos Z et al., 2002, Genes Dev, Vol. 16, pp. 720-728. In addition, "hsa-miR-92a-2-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-92a-2" (miRBase Accession No. MI0000094, Sequence ID No. 529).

[0340] As used herein, the terms "hsa-miR-128-1-5p gene" or "hsa-miR-128-1-5p" include the hsa-miR-128-1-5p gene (miRBase Accession No. MIMAT0026477) described in Sequence ID No. 259, as well as other species homologs or orthologs. The hsa-miR-128-1-5p gene can be obtained by the method described by Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, "hsa-miR-128-1-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-128-1" (miRBase Accession No. MI0000447, Sequence ID No. 530).

[0341] As used herein, the terms "hsa-miR-1290 gene" or "hsa-miR-1290" include the hsa-miR-1290 gene (miRBase Accession No. MIMAT0005880) described in Sequence ID No. 260, as well as other species homologs or orthologs. The hsa-miR-1290 gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, "hsa-miR-1290" is known to have a hairpin-like structure as its precursor, "hsa-mir-1290" (miRBase Accession No. MI0006352, Sequence ID No. 531).

[0342] As used herein, the terms "hsa-miR-211-3p gene" or "hsa-miR-211-3p" include the hsa-miR-211-3p gene (miRBase Accession No. MIMAT0022694) described in Sequence ID No. 261, as well as other species homologs or orthologs. The hsa-miR-211-3p gene can be obtained by the method described by Lim LP et al., 2003, Science, Vol. 299, p. 1540. In addition, "hsa-miR-211-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-211" (miRBase Accession No. MI0000287, Sequence ID No. 532).

[0343] As used herein, the terms "hsa-miR-744-5p gene" or "hsa-miR-744-5p" include the hsa-miR-744-5p gene (miRBase Accession No. MIMAT0004945) described in Sequence ID No. 262, as well as other species homologs or orthologs. The hsa-miR-744-5p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-744-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-744" (miRBase Accession No. MI0005559, Sequence ID No. 533).

[0344] As used herein, the terms "hsa-miR-135a-3p gene" or "hsa-miR-135a-3p" include the hsa-miR-135a-3p gene (miRBase Accession No. MIMAT0004595) described in Sequence ID No. 263, as well as other species homologs or orthologs. The hsa-miR-135a-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, "hsa-miR-135a-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-135a-1" (miRBase Accession No. MI0000452, Sequence ID No. 534).

[0345] As used herein, the terms "hsa-miR-451a gene" or "hsa-miR-451a" include the hsa-miR-451a gene (miRBase Accession No. MIMAT0001631) described in Sequence ID No. 264, as well as other species homologs or orthologs. The hsa-miR-451a gene can be obtained by the method described by Altuvia Y et al., 2005, Nucleic Acids Res, Vol. 33, pp. 2697-2706. In addition, "hsa-miR-451a" is known to have a hairpin-like structure as its precursor, "hsa-mir-451a" (miRBase Accession No. MI0001729, Sequence ID No. 535).

[0346] As used herein, the terms "hsa-miR-625-3p gene" or "hsa-miR-625-3p" include the hsa-miR-625-3p gene (miRBase Accession No. MIMAT0004808) described in Sequence ID No. 265, as well as other species homologs or orthologs. The hsa-miR-625-3p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-625-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-625" (miRBase Accession No. MI0003639, Sequence ID No. 536).

[0347] As used herein, the terms "hsa-miR-92a-3p gene" or "hsa-miR-92a-3p" include the hsa-miR-92a-3p gene (miRBase Accession No. MIMAT0000092) described in Sequence ID No. 266, as well as other species homologs or orthologs. The hsa-miR-92a-3p gene can be obtained by the method described by Mourelatos Z et al., 2002, Genes Dev, Vol. 16, pp. 720-728. In addition, "hsa-miR-92a-3p" is known to have hairpin-like precursors, "hsa-mir-92a-1, hsa-mir-92a-2" (miRBase Accession No. MI0000093, MI0000094, Sequence ID No. 537, 529).

[0348] As used herein, the terms "hsa-miR-422a gene" or "hsa-miR-422a" include the hsa-miR-422a gene (miRBase Accession No. MIMAT0001339) described in Sequence ID No. 267, as well as other species homologs or orthologs. The hsa-miR-422a gene can be obtained by the method described by Kasashima K et al., 2004, Biochem Biophys Res Commun, Vol. 322, pp. 403-410. In addition, "hsa-miR-422a" is known to have a hairpin-like structure as its precursor, "hsa-mir-422a" (miRBase Accession No. MI0001444, Sequence ID No. 538).

[0349] As used herein, the terms "hsa-miR-642a-3p gene" or "hsa-miR-642a-3p" include the hsa-miR-642a-3p gene (miRBase Accession No. MIMAT0020924) described in Sequence ID No. 268, as well as other species homologs or orthologs. The hsa-miR-642a-3p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-642a-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-642a" (miRBase Accession No. MI0003657, Sequence ID No. 539).

[0350] As used herein, the terms "hsa-miR-483-5p gene" or "hsa-miR-483-5p" include the hsa-miR-483-5p gene (miRBase Accession No. MIMAT0004761) described in Sequence ID No. 269, as well as other species homologs or orthologs. The hsa-miR-483-5p gene can be obtained by the method described by Fu H et al., 2005, FEBS Lett, Vol. 579, pp. 3849-3854. In addition, "hsa-miR-483-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-483" (miRBase Accession No. MI0002467, Sequence ID No. 540).

[0351] As used herein, the terms "hsa-miR-652-5p gene" or "hsa-miR-652-5p" include the hsa-miR-652-5p gene (miRBase Accession No. MIMAT0022709) described in Sequence ID No. 270, as well as other species homologs or orthologs. The hsa-miR-652-5p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-652-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-652" (miRBase Accession No. MI0003667, Sequence ID No. 541).

[0352] As used herein, the terms "hsa-miR-24-3p gene" or "hsa-miR-24-3p" include the hsa-miR-24-3p gene (miRBase Accession No. MIMAT0000080) described in Sequence ID No. 271, as well as other species homologs or orthologs. The hsa-miR-24-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. In addition, "hsa-miR-24-3p" is known to have hairpin-like precursors, "hsa-mir-24-1, hsa-mir-24-2" (miRBase Accession No. MI0000080, MI0000081, Sequence ID No. 542, 543).

[0353] As used herein, the terms "hsa-miR-23b-3p gene" or "hsa-miR-23b-3p" include the hsa-miR-23b-3p gene (miRBase Accession No. MIMAT0000418) described in Sequence ID No. 272, as well as other species homologs or orthologs. The hsa-miR-23b-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, "hsa-miR-23b-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-23b" (miRBase Accession No. MI0000439, Sequence ID No. 544).

[0354] As used herein, the terms "hsa-miR-23a-3p gene" or "hsa-miR-23a-3p" include the hsa-miR-23a-3p gene (miRBase Accession No. MIMAT0000078) described in Sequence ID No. 273, as well as other species homologs or orthologs. The hsa-miR-23a-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. In addition, "hsa-miR-23a-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-23a" (miRBase Accession No. MI0000079, Sequence ID No. 545).

[0355] As used herein, the terms "hsa-miR-92b-3p gene" or "hsa-miR-92b-3p" include the hsa-miR-92b-3p gene (miRBase Accession No. MIMAT0003218) described in Sequence ID No. 274, as well as other species homologs or orthologs. The hsa-miR-92b-3p gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, "hsa-miR-92b-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-92b" (miRBase Accession No. MI0003560, Sequence ID No. 527).

[0356] As used herein, the terms "hsa-miR-22-3p gene" or "hsa-miR-22-3p" include the hsa-miR-22-3p gene (miRBase Accession No. MIMAT0000077) described in Sequence ID No. 275, as well as other species homologs or orthologs. The hsa-miR-22-3p gene can be obtained by the method described by Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. In addition, "hsa-miR-22-3p" is known to have a hairpin-like structure as its precursor, "hsa-mir-22" (miRBase Accession No. MI0000078, Sequence ID No. 546).

[0357] Furthermore, when mature miRNAs are excised from RNA precursors that have a hairpin-like structure, one to several bases may be shortened or lengthened at the beginning and end of the sequence, or base substitutions may occur, resulting in mutants called isomiRs (Morin RD. et al., 2008, Genome Res., Vol. 18, pp. 610-621). In addition to the nucleotide sequences represented by SEQ ID NOs. 1 to 275, miRBase Release 21 also shows numerous mutants and fragments of nucleotide sequences represented by SEQ ID NOs. 547 to 842, which are called isomiRs. These mutants can also be obtained as miRNAs of nucleotide sequences represented by SEQ ID NOs. 1 to 275. That is, the sequence numbers 2, 3, 4, 8, 11, 14, 17, 18, 20, 24, 25, 29, 34, 36, 39, 40, 41, 42, 43, 44, 45, 51, 53, 55, 57, 59, 62, 63, 66, 67, 69, 70, 71, 72, 73, 75, 76, 78, 79, 84, 87, 88, 90, 94, 9 of the present invention 6, 98, 101, 102, 103, 104, 105, 110, 112, 113, 117, 119, 121, 122, 123, 124, 125, 127, 130, 136, 140, 141, 146, 148, 151, 153, 154, 159, 164, 166, 170, 175, 180, 184, 185, 189, 1 90, 193, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 207, 210, 212, 213, 215, 217, 218, 219, 220, 221, 223, 224, 229, 232, 233, 238, 239, 240, 241, 248, 249, 250, 251, 252 Among the variants of polynucleotides consisting of the base sequences represented by 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 269, 270, 271, 272, 274 and 275, or the base sequences in which u is t, for example, the longest variants registered in miRBase Release 21 are, respectively, sequence numbers 547, 549, 551, 554, 556, 560, 563, 565, 567, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590,592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 623, 625, 627, 629, 632, 634, 636, 638, 641, 644, 646, 649, 651, 653, 655, 657, 661, 663, 665, 668, 670, 672, 674, 676, 678, 680, 682, 685, 687, 689, 691, 694, 696, 698, 700, 702, 704, 707, 709, 711, 714, 717, 720, 722, 725, 72 Examples of polynucleotides include those represented by 7, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823, 825, 827, 830, 832, 834, 836, 839, and 841. Furthermore, regarding the sequence numbers 2, 3, 4, 8, 11, 14, 17, 18, 20, 24, 25, 29, 34, 36, 39, 40, 41, 42, 43, 44, 45, 51, 53, 55, 57, 59, 62, 63, 66, 67, 69, 70, 71, 72, 73, 75, 76, 78, 79, 84, 87, 88, 90, 94, 96, 98, 101, 102, 103, 104, 105, 110, 112, 113, 117, 119, 121, 122, 123, 124, 125, 127, 130, 136, 140, 141, 146, 148, 151, 153, 154, 159 of the present invention ,164,166,170,175,180,184,185,189,190,193,195,196,197,198,199,201,202,203,204,205,207,210,212,213,215,217,218,219,220,221,223 ,224,229,232,233,238,239,240,241,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,269,270,271,272,Among the variants of polynucleotides consisting of the base sequences represented by 274 and 275, or the base sequence in which u is t, for example, the shortest variants registered in miRBase Release 21 are, respectively, SEQ ID NOs: 548, 550, 552, 555, 557, 561, 564, 566, 568, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 624, 626, 628, 630, 633, 635, 637, 639, 642, 645, 647, 650, 652, 654, 656, 658, 662, 664, 666, 669, 671, 673, 675, 677, 679, 681, 683, 686, 688, 690, 692, 695, 6 97, 699, 701, 703, 705, 708, 710, 712, 715, 718, 721, 723, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 77 Examples of polynucleotides include those represented by sequences 7, 779, 781, 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 831, 833, 835, 837, 840, and 842. In addition to these variants and fragments, examples of polynucleotides that are isomiRs with sequence numbers 1-275, registered in miRBase, also include those with sequence numbers 1-275. Furthermore, examples of polynucleotides containing a base sequence represented by any of sequence numbers 1-275 include the precursor polynucleotides represented by sequence numbers 276-546.

[0358] Table 1 lists the gene names and miRBase Accession No. (registration number) for the genes represented by sequence numbers 1 to 842.

[0359] In this specification, "specifically binding" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and is substantially unable to bind to other nucleic acids.

[0360] [Table 1] TIFF0007912242000002.tif243129TIFF0007912242000003.tif243131TIFF00079122420 00004.tif243134TIFF0007912242000005.tif243132TIFF0007912242000006.tif243132 TIFF0007912242000007.tif242132TIFF0007912242000008.tif243132TIFF00079122420 00009.tif242130TIFF0007912242000010.tif242131TIFF0007912242000011.tif242130 TIFF0007912242000012.tif243131TIFF0007912242000013.tif243131TIFF00079122420 00014.tif243131TIFF0007912242000015.tif243131TIFF0007912242000016.tif244132 TIFF0007912242000017.tif243133TIFF0007912242000018.tif243132TIFF00079122420 00019.tif243131TIFF0007912242000020.tif243132TIFF0007912242000021.tif243131 TIFF0007912242000022.tif243135TIFF0007912242000023.tif204134 [Effects of the Invention]

[0361] This invention makes it possible to easily and accurately detect ovarian tumors. For example, by using the measured expression levels of one to several miRNAs in the patient's blood, serum, and / or plasma, which can be collected minimally invasively, it is possible to easily detect whether or not a patient has an ovarian tumor.

[0362] This specification includes the disclosures of Japanese Patent Application No. 2017-090799, which forms the basis of the priority claim of this application. [Brief explanation of the drawing]

[0363] [Figure 1] This figure shows the sequence relationship between hsa-miR-4433a-5p (represented by sequence number 128) and hsa-miR-4433a-3p (represented by sequence number 151), which are generated from the precursor hsa-mir-4433a (represented by sequence number 405). [Figure 2] Left figure: The vertical axis shows the measured levels of hsa-miR-4675 (SEQ ID NO: 1) expression in the serum of healthy individuals (280 people) and ovarian tumor patients (303 people) selected as the learning sample group. The horizontal line in the figure indicates the threshold (7.75) for distinguishing between the two groups, optimized by Fisher's discriminant analysis. Right figure: The vertical axis shows the measured levels of hsa-miR-4675 (SEQ ID NO: 1) expression in healthy individuals (120 people) and ovarian tumor patients (131 people) selected as the test sample group. The horizontal line in the figure indicates the threshold (7.75) for distinguishing between the two groups, set for the learning sample group. [Figure 3]Figure above: Serum samples of hsa-miR-296-5p (SEQ ID NO: 256), hsa-miR-3131 (SEQ ID NO: 196), hsa-miR-1290 (SEQ ID NO: 260), hsa-miR-642a-3p (SEQ ID NO: 268), and hsa-mi from subjects without ovarian tumors (280 healthy individuals, 257 patients with benign bone and soft tissue tumors and benign breast diseases, and 280 patients with cancers other than ovarian cancer, totaling 817 people) and patients with ovarian tumors (303 people), selected as the learning sample group. A discriminant formula was created using Fisher's discriminant analysis based on the measured expression levels of R-128-2-5p (SEQ ID NO: 252) (1.390xhsa-miR-296-5p-1.095xhsa-miR-3131+0.201xhsa-miR-1290+0.695xhsa-miR-642a-3p+0.306xhsa-miR-128-2-5p-13.186). The discriminant score obtained from this formula is plotted on the vertical axis, and the sample groups are plotted on the horizontal axis. The dotted line in the figure indicates the discriminant boundary where the two groups are distinguished by a discriminant score of 0. Figure below: Serum levels of hsa-miR-296-5p (SEQ ID NO: 256), hsa-miR-3131 (SEQ ID NO: 196), hsa-miR-1290 (SEQ ID NO: 260), hsa-miR-642a-3p (SEQ ID NO: 268), and from subjects selected as test sample groups: 351 subjects in total (120 healthy individuals, 111 patients with benign bone and soft tissue tumors and benign breast diseases, and 120 patients with cancers other than ovarian cancer) and 131 patients with ovarian tumors. The graph shows the discriminant score obtained by substituting the measured expression levels of hsa-miR-128-2-5p (sequence number 252) into the discriminant formula (1.390xhsa-miR-296-5p-1.095xhsa-miR-3131+0.201xhsa-miR-1290+0.695xhsa-miR-642a-3p+0.306xhsa-miR-128-2-5p-13.186) created for the training sample group, with the discriminant score on the vertical axis and the sample group on the horizontal axis. The dotted line in the figure indicates the discriminant boundary where the discriminant score is 0, thus distinguishing between the two groups. [Modes for carrying out the invention]

[0364] The present invention will be described in more detail below. 1. Target nucleic acids for ovarian tumorsThe primary target nucleic acids as ovarian tumor markers for detecting the presence and / or absence of ovarian tumors or ovarian tumor cells using nucleic acids such as nucleic acid probes or primers for ovarian tumor detection as defined above in the present invention include hsa-miR-4675, hsa-miR-4783-3p, hsa-miR-1228-5p, hsa-miR-4532, hsa-miR-6802-5p, hsa-miR-6784-5p, hsa-miR-3940-5p, hsa-miR-1307-3p, hsa-miR-8073, hsa-miR-3184-5p, hs a-miR-1233-5p, hsa-miR-6088, hsa-miR-5195-3p, hsa-miR-320b, hsa-miR-4649-5p, hsa-miR-6800-5p, hsa-miR-1343-3p, hsa-miR-4730, hsa-miR -6885-5p, hsa-miR-5100, hsa-miR-1203, hsa-miR-6756-5p, hsa-miR-373-5p, hsa-miR-1268a, hsa-miR-1260b, hsa-miR-4258, hsa-miR-4697-5p, h sa-miR-1469, hsa-miR-4515, hsa-miR-6861-5p, hsa-miR-6821-5p, hsa-miR-575, hsa-miR-6805-5p, hsa-miR-4758-5p, hsa-miR-3663-3p, hsa-miR -4530, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-miR-885-3p, hsa-miR-1273g-3p, hsa-miR-4787-3p, hsa-miR-4454, hsa-miR-4706, hsa-miR-1249 -3p, hsa-miR-887-3p, hsa-miR-6786-5p, hsa-miR-1238-5p, hsa-miR-6749-5p, hsa-miR-6729-5p, hsa-miR-6825-5p, hsa-miR-663b, hsa-miR-6858 -5p, hsa-miR-4690-5p, hsa-miR-6765-5p, hsa-miR-4710, hsa-miR-6775-5p, hsa-miR-371a-5p, hsa-miR-6816-5p, hsa-miR-296-3p, hsa-miR-7977,hsa-miR-8069, hsa-miR-6515-3p, hsa-miR-4687-5p, hsa-miR-1343-5p, hsa-miR-7110-5p, hsa-miR-4525, hsa-miR-3158-5p, hsa-miR-6787-5p, hs a-miR-614, hsa-miR-4689, hsa-miR-1185-2-3p, hsa-miR-1268b, hsa-miR-1228-3p, hsa-miR-1185-1-3p, hsa-miR-940, hsa-miR-939-5p, hsa-miR- 6757-5p, hsa-miR-1275, hsa-miR-5001-5p, hsa-miR-6826-5p, hsa-miR-6765-3p, hsa-miR-3679-3p, hsa-miR-4718, hsa-miR-4286, hsa-miR-8059 hsa-miR-4447, hsa-miR-4448, hsa-miR-658, hsa-miR-6766-3p, hsa-miR-197-5p, hsa-miR-6887-5p, hsa-miR-6742-5p, hsa-miR-6729-3p, hsa-miR- 5090, hsa-miR-7975, hsa-miR-4505, hsa-miR-6889-5p, hsa-miR-4708-3p, hsa-miR-6131, hsa-miR-1225-3p, hsa-miR-6132, hsa-miR-4734, hsa-mi R-3194-3p, hsa-miR-638, hsa-miR-2467-3p, hsa-miR-4728-5p, hsa-miR-5572, hsa-miR-6789-5p, hsa-miR-8063, hsa-miR-4429, hsa-miR-6840-3p hsa-miR-4476 hsa-miR-675-5p hsa-miR-711 hsa-miR-6875-5p hsa-miR-3160-5p hsa-miR-1908-5p hsa-miR-6726-5p hsa-miR-1913 hsa-mi R-8071, hsa-miR-3648, hsa-miR-4732-5p, hsa-miR-4787-5p, hsa-miR-3917, hsa-miR-619-5p, hsa-miR-1231, hsa-miR-342-5p, hsa-miR-4433a-5phsa-miR-6766-5p, hsa-miR-4707-5p, hsa-miR-7114-5p, hsa-miR-6872-3p, hsa-miR-6780b-5p, hsa-miR-7845-5p, hsa-miR-6798-3p, hsa-miR-665 hsa-miR-6848-5p, hsa-miR-5008-5p, hsa-miR-4294, hsa-miR-6511a-5p, hsa-miR-4435, hsa-miR-4747-3p, hsa-miR-6880-3p, hsa-miR-6869-5p, hs a-miR-7150, hsa-miR-1260a, hsa-miR-6877-5p, hsa-miR-6721-5p, hsa-miR-4656, hsa-miR-1229-5p, hsa-miR-4433a-3p, hsa-miR-4274, hsa-miR-4 419b, hsa-miR-4674, hsa-miR-6893-5p, hsa-miR-6763-3p, hsa-miR-6762-5p, hsa-miR-6738-5p, hsa-miR-4513, hsa-miR-6746-5p, hsa-miR-6880-5 p, hsa-miR-4736, hsa-miR-718, hsa-miR-6717-5p, hsa-miR-7847-3p, hsa-miR-760, hsa-miR-1199-5p, hsa-miR-6813-5p, hsa-miR-6769a-5p, hsa-m iR-1193, hsa-miR-7108-3p, hsa-miR-6741-5p, hsa-miR-4298, hsa-miR-6796-3p, hsa-miR-4750-5p, hsa-miR-6785-5p, hsa-miR-1292-3p, hsa-miR- 4749-3p, hsa-miR-6800-3p, hsa-miR-4722-5p, hsa-miR-4746-3p, hsa-miR-4450, hsa-miR-6795-5p, hsa-miR-365a-5p, hsa-miR-498, hsa-miR-6797 -5p, hsa-miR-1470, hsa-miR-6851-5p, hsa-miR-1247-3p, hsa-miR-5196-5p, hsa-miR-208a-5p, hsa-miR-6842-5p, hsa-miR-150-3p, hsa-miR-4534hsa-miR-3135b, hsa-miR-3131, hsa-miR-4792, hsa-miR-6510-5p, hsa-miR-504-3p, hsa-miR-3619-3p, hsa-miR-671-5p, hsa- miR-4667-5p, hsa-miR-4430, hsa-miR-3195, hsa-miR-3679-5p, hsa-miR-6076, hsa-miR-6515-5p, hsa-miR-6820-5p, hsa-miR -4634, hsa-miR-187-5p, hsa-miR-6763-5p, hsa-miR-1908-3p, hsa-miR-1181, hsa-miR-6782-5p, hsa-miR-5010-5p, hsa-miR- 6870-5p, hsa-miR-6124, hsa-miR-1249-5p, hsa-miR-6511b-5p, hsa-miR-1254, hsa-miR-4727-3p, hsa-miR-4259, hsa-miR-477 1, hsa-miR-3622a-5p, hsa-miR-4480, hsa-miR-4740-5p, hsa-miR-6777-5p, hsa-miR-6794-5p, hsa-miR-4687-3p, hsa-miR-67 43-5p, hsa-miR-6771-5p, hsa-miR-3141, hsa-miR-3162-5p, hsa-miR-4271, hsa-miR-1227-5p, hsa-miR-4257, hsa-miR-4270, h It contains at least one miRNA selected from the group consisting of sa-miR-4516, hsa-miR-4651, hsa-miR-4725-3p, hsa-miR-6125, hsa-miR-6732-5p, hsa-miR-6791-5p, hsa-miR-6819-5p, hsa-miR-6891-5p, hsa-miR-7108-5p, hsa-miR-7109-5p, hsa-miR-642b-3p, and hsa-miR-642a-3p. Furthermore, other ovarian tumor markers that can be combined with these miRNAs include, namely, hsa-miR-320a, hsa-miR-663a, hsa-miR-328-5p, hsa-miR-128-2-5p, hsa-miR-125a-3p, hsa-miR-191-5p, hsa-miR-92b-5p,hsa-miR-296-5p, hsa-miR-1246, hsa-miR-92a-2-5p, hsa-miR-128-1-5p, hsa-miR-1290, hsa-mi R-211-3p, hsa-miR-744-5p, hsa-miR-135a-3p, hsa-miR-451a, hsa-miR-625-3p, hsa-miR-92a-3p At least one miRNA selected from the group consisting of hsa-miR-422a, hsa-miR-483-5p, hsa-miR-652-5p, hsa-miR-24-3p, hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-92b-3p, and hsa-miR-22-3p can also be preferably used as a target nucleic acid.

[0365] The above miRNAs include, for example, human genes containing a base sequence represented by any of sequence numbers 1 to 275 (i.e., hsa-miR-4675, hsa-miR-4783-3p, hsa-miR-1228-5p, hsa-miR-4532, hsa-miR-6802-5p, hsa-miR-6784-5p, hsa-miR-3940-5p, hsa-miR-1307-3p, hsa-miR-8073, hsa-miR-3184-5p, hsa-miR-1233-5p, hsa-miR-6088, hsa-miR-5195- 3p, hsa-miR-320b, hsa-miR-4649-5p, hsa-miR-6800-5p, hsa-miR-1343-3p, hsa-miR-4730, hsa-miR-6885-5p, hsa-miR-5100, hsa-miR-1203, hsa-mi R-6756-5p, hsa-miR-373-5p, hsa-miR-1268a, hsa-miR-1260b, hsa-miR-4258, hsa-miR-4697-5p, hsa-miR-1469, hsa-miR-4515, hsa-miR-6861-5p, h sa-miR-6821-5p, hsa-miR-575, hsa-miR-6805-5p, hsa-miR-4758-5p, hsa-miR-3663-3p, hsa-miR-4530, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-m iR-885-3p, hsa-miR-1273g-3p, hsa-miR-4787-3p, hsa-miR-4454, hsa-miR-4706, hsa-miR-1249-3p, hsa-miR-887-3p, hsa-miR-6786-5p, hsa-miR-1 238-5p, hsa-miR-6749-5p, hsa-miR-6729-5p, hsa-miR-6825-5p, hsa-miR-663b, hsa-miR-6858-5p, hsa-miR-4690-5p, hsa-miR-6765-5p, hsa-miR-4 710, hsa-miR-6775-5p, hsa-miR-371a-5p, hsa-miR-6816-5p, hsa-miR-296-3p, hsa-miR-7977, hsa-miR-8069, hsa-miR-6515-3p, hsa-miR-4687-5p,hsa-miR-1343-5p, hsa-miR-7110-5p, hsa-miR-4525, hsa-miR-3158-5p, hsa-miR-6787-5p, hsa-miR-614, hsa-miR-4689, hsa-miR-1185-2-3p, hsa- miR-1268b, hsa-miR-1228-3p, hsa-miR-1185-1-3p, hsa-miR-940, hsa-miR-939-5p, hsa-miR-6757-5p, hsa-miR-1275, hsa-miR-5001-5p, hsa-miR-6 826-5p, hsa-miR-6765-3p, hsa-miR-3679-3p, hsa-miR-4718, hsa-miR-4286, hsa-miR-8059, hsa-miR-4447, hsa-miR-4448, hsa-miR-658, hsa-miR- 6766-3p, hsa-miR-197-5p, hsa-miR-6887-5p, hsa-miR-6742-5p, hsa-miR-6729-3p, hsa-miR-5090, hsa-miR-7975, hsa-miR-4505, hsa-miR-6889-5p hsa-miR-4708-3p hsa-miR-6131 hsa-miR-1225-3p hsa-miR-6132 hsa-miR-4734 hsa-miR-3194-3p hsa-miR-638 hsa-miR-2467-3p hsa-miR- 4728-5p, hsa-miR-5572, hsa-miR-6789-5p, hsa-miR-8063, hsa-miR-4429, hsa-miR-6840-3p, hsa-miR-4476, hsa-miR-675-5p, hsa-miR-711, hsa-mi R-6875-5p, hsa-miR-3160-5p, hsa-miR-1908-5p, hsa-miR-6726-5p, hsa-miR-1913, hsa-miR-8071, hsa-miR-3648, hsa-miR-4732-5p, hsa-miR-4787 -5p, hsa-miR-3917, hsa-miR-619-5p, hsa-miR-1231, hsa-miR-342-5p, hsa-miR-4433a-5p, hsa-miR-6766-5p, hsa-miR-4707-5p, hsa-miR-7114-5phsa-miR-6872-3p, hsa-miR-6780b-5p, hsa-miR-7845-5p, hsa-miR-6798-3p, hsa-miR-665, hsa-miR-6848-5p, hsa-miR-5008-5p, hsa-miR-4294, hs a-miR-6511a-5p, hsa-miR-4435, hsa-miR-4747-3p, hsa-miR-6880-3p, hsa-miR-6869-5p, hsa-miR-7150, hsa-miR-1260a, hsa-miR-6877-5p, hsa-m iR-6721-5p, hsa-miR-4656, hsa-miR-1229-5p, hsa-miR-4433a-3p, hsa-miR-4274, hsa-miR-4419b, hsa-miR-4674, hsa-miR-6893-5p, hsa-miR-676 3-3p, hsa-miR-6762-5p, hsa-miR-6738-5p, hsa-miR-4513, hsa-miR-6746-5p, hsa-miR-6880-5p, hsa-miR-4736, hsa-miR-718, hsa-miR-6717-5p, h sa-miR-7847-3p, hsa-miR-760, hsa-miR-1199-5p, hsa-miR-6813-5p, hsa-miR-6769a-5p, hsa-miR-1193, hsa-miR-7108-3p, hsa-miR-6741-5p, hsa -miR-4298, hsa-miR-6796-3p, hsa-miR-4750-5p, hsa-miR-6785-5p, hsa-miR-1292-3p, hsa-miR-4749-3p, hsa-miR-6800-3p, hsa-miR-4722-5p, hs a-miR-4746-3p, hsa-miR-4450, hsa-miR-6795-5p, hsa-miR-365a-5p, hsa-miR-498, hsa-miR-6797-5p, hsa-miR-1470, hsa-miR-6851-5p, hsa-miR- 1247-3p, hsa-miR-5196-5p, hsa-miR-208a-5p, hsa-miR-6842-5p, hsa-miR-150-3p, hsa-miR-4534, hsa-miR-3135b, hsa-miR-3131, hsa-miR-4792hsa-miR-6510-5p, hsa-miR-504-3p, hsa-miR-3619-3p, hsa-miR-671-5p, hsa-miR-4667-5p, hsa-miR-4430, hsa-miR-3195, hsa-miR-3679-5p, hsa-miR-6076, hsa-miR-6515-5p, hsa-miR-6820-5p, hsa-miR-4634, hsa-miR-187-5p, hsa-miR-6763-5p, hsa-miR-1908-3p, hsa-miR-1181, hsa-miR-6 782-5p, hsa-miR-5010-5p, hsa-miR-6870-5p, hsa-miR-6124, hsa-miR-1249-5p, hsa-miR-6511b-5p, hsa-miR-1254, hsa-miR-4727-3p, hsa-miR-4 259, hsa-miR-4771, hsa-miR-3622a-5p, hsa-miR-4480, hsa-miR-4740-5p, hsa-miR-6777-5p, hsa-miR-6794-5p, hsa-miR-4687-3p, hsa-miR-6743- 5p, hsa-miR-6771-5p, hsa-miR-3141, hsa-miR-3162-5p, hsa-miR-4271, hsa-miR-1227-5p, hsa-miR-4257, hsa-miR-4270, hsa-miR-4516, hsa-miR -4651, hsa-miR-4725-3p, hsa-miR-6125, hsa-miR-6732-5p, hsa-miR-6791-5p, hsa-miR-6819-5p, hsa-miR-6891-5p, hsa-miR-7108-5p, hsa-miR-6 42b-3p、hsa-miR-642a-3p、hsa-miR-7109-5p、hsa-miR-320a、hsa-miR-66 3a、hsa-miR-328-5p、hsa-miR-128-2-5p、hsa-miR-125a-3p、hsa-miR-191 -5p, hsa-miR-92b-5p, hsa-miR-296-5p, hsa-miR-1246, hsa-miR-92a-2-5p, hsa-miR-128-1-5p, hsa-miR-1290, hsa-miR-211-3p, hsa-miR-744-5pThis includes hsa-miR-135a-3p, hsa-miR-451a, hsa-miR-625-3p, hsa-miR-92a-3p, hsa-miR-422a, hsa-miR-483-5p, hsa-miR-652-5p, hsa-miR-24-3p, hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-92b-3p, and hsa-miR-22-3p), their congeners, their transcripts, and / or their variants or derivatives. Here, genes, congeners, transcripts, variants, and derivatives are defined as above.

[0366] Preferred target nucleic acids are human genes containing a base sequence represented by any of SEQ ID NOs: 1 to 842, their transcripts, more preferably the transcripts, i.e., miRNAs, and their precursor RNAs, pri-miRNA or pre-miRNA.

[0367] The primary target genes are the hsa-miR-4675 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0368] The second target gene is the hsa-miR-4783-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0369] The third target gene is the hsa-miR-1228-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0370] The fourth target gene is the hsa-miR-4532 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0371] The fifth target gene is the hsa-miR-6802-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0372] The sixth target gene is the hsa-miR-6784-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0373] The seventh target gene is the hsa-miR-3940-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0374] The eighth target gene is the hsa-miR-1307-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0375] The ninth target gene is the hsa-miR-8073 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0376] The tenth target gene is the hsa-miR-3184-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0377] The eleventh target gene is the hsa-miR-1233-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0378] The twelfth target gene is the hsa-miR-6088 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0379] The 13th target gene is the hsa-miR-5195-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0380] The 14th target gene is the hsa-miR-320b gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0381] The 15th target gene is the hsa-miR-4649-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0382] The 16th target gene is the hsa-miR-6800-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0383] The 17th target gene is the hsa-miR-1343-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0384] The 18th target gene is the hsa-miR-4730 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0385] The 19th target gene is the hsa-miR-6885-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0386] The 20th target gene is the hsa-miR-5100 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0387] The 21st target gene is the hsa-miR-1203 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0388] The 22nd target gene is the hsa-miR-6756-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0389] The 23rd target gene is the hsa-miR-373-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0390] The 24th target gene is the hsa-miR-1268a gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0391] The 25th target gene is the hsa-miR-1260b gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0392] The 26th target gene is the hsa-miR-4258 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0393] The 27th target gene is the hsa-miR-4697-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0394] The 28th target gene is the hsa-miR-1469 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0395] The 29th target gene is the hsa-miR-4515 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0396] The 30th target gene is the hsa-miR-6861-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0397] The 31st target gene is the hsa-miR-6821-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0398] The 32nd target gene is the hsa-miR-575 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0399] The 33rd target gene is the hsa-miR-6805-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0400] The 34th target gene is the hsa-miR-4758-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0401] The 35th target gene is the hsa-miR-3663-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0402] The 36th target gene is the hsa-miR-4530 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0403] The 37th target gene is the hsa-miR-6798-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0404] The 38th target gene is the hsa-miR-6781-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0405] The 39th target gene is the hsa-miR-885-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0406] The 40th target gene is the hsa-miR-1273g-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0407] The 41st target gene is the hsa-miR-4787-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0408] The 42nd target gene is the hsa-miR-4454 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0409] The 43rd target gene is the hsa-miR-4706 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0410] The 44th target gene is the hsa-miR-1249-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0411] The 45th target gene is the hsa-miR-887-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0412] The 46th target gene is the hsa-miR-6786-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0413] The 47th target gene is the hsa-miR-1238-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0414] The 48th target gene is the hsa-miR-6749-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0415] The 49th target gene is the hsa-miR-6729-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0416] The 50th target gene is the hsa-miR-6825-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0417] The 51st target gene is the hsa-miR-663b gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0418] The 52nd target gene is the hsa-miR-6858-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0419] The 53rd target gene is the hsa-miR-4690-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0420] The 54th target gene is the hsa-miR-6765-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0421] The 55th target gene is the hsa-miR-4710 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0422] The 56th target gene is the hsa-miR-6775-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0423] The 57th target gene is the hsa-miR-371a-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0424] The 58 target genes are the hsa-miR-6816-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of these genes or their transcripts can serve as markers for ovarian tumors.

[0425] The 59th target gene is the hsa-miR-296-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0426] The 60th target gene is the hsa-miR-7977 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0427] The 61st target gene is the hsa-miR-8069 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0428] The 62nd target gene is the hsa-miR-6515-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0429] The 63rd target gene is the hsa-miR-4687-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0430] The 64th target gene is the hsa-miR-1343-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0431] The 65th target gene is the hsa-miR-7110-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0432] The 66th target gene is the hsa-miR-4525 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0433] The 67th target gene is the hsa-miR-3158-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0434] The 68th target gene is the hsa-miR-6787-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0435] The 69th target gene is the hsa-miR-614 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0436] The 70th target gene is the hsa-miR-4689 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0437] The 71st target gene is the hsa-miR-1185-2-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0438] The 72nd target gene is the hsa-miR-1268b gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0439] The 73rd target gene is the hsa-miR-1228-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0440] The 74th target gene is the hsa-miR-1185-1-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0441] The 75th target gene is the hsa-miR-940 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0442] The 76th target gene is the hsa-miR-939-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0443] The 77th target gene is the hsa-miR-6757-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0444] The 78th target gene is the hsa-miR-1275 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0445] The 79th target gene is the hsa-miR-5001-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0446] The 80th target gene is the hsa-miR-6826-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0447] The 81st target gene is the hsa-miR-6765-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0448] The 82nd target gene is the hsa-miR-3679-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0449] The 83rd target gene is the hsa-miR-4718 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0450] The 84th target gene is the hsa-miR-4286 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0451] The 85th target gene is the hsa-miR-8059 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0452] The 86th target gene is the hsa-miR-4447 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0453] The 87th target gene is the hsa-miR-4448 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0454] The 88th target gene is the hsa-miR-658 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0455] The 89th target gene is the hsa-miR-6766-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0456] The 90th target gene is the hsa-miR-197-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0457] The 91st target gene is the hsa-miR-6887-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0458] The 92nd target gene is the hsa-miR-6742-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0459] The 93rd target gene is the hsa-miR-6729-3p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0460] The 94th target gene is the hsa-miR-5090 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0461] The 95th target gene is the hsa-miR-7975 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0462] The 96th target gene is the hsa-miR-4505 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0463] The 97th target gene is the hsa-miR-6889-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0464] The 98th target gene is the hsa-miR-4708-3p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0465] The 99th target gene is the hsa-miR-6131 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0466] The 100th target gene is the hsa-miR-1225-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0467] The 101st target gene is the hsa-miR-6132 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0468] The 102nd target gene is the hsa-miR-4734 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0469] The 103rd target gene is the hsa-miR-3194-3p gene, its homologs, their transcripts, or their mutants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0470] The 104th target gene is the hsa-miR-638 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0471] The 105th target gene is the hsa-miR-2467-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0472] The 106th target gene is the hsa-miR-4728-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0473] The 107th target gene is the hsa-miR-5572 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0474] The 108th target gene is the hsa-miR-6789-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0475] The 109th target gene is the hsa-miR-8063 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0476] The 110th target gene is the hsa-miR-4429 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0477] The 111th target gene is the hsa-miR-6840-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0478] The 112th target gene is the hsa-miR-4476 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0479] The 113th target gene is the hsa-miR-675-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0480] The 114th target gene is the hsa-miR-711 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0481] The 115th target gene is the hsa-miR-6875-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0482] The 116th target gene is the hsa-miR-3160-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0483] The 117th target gene is the hsa-miR-1908-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0484] The 118th target gene is the hsa-miR-6726-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0485] The 119th target gene is the hsa-miR-1913 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0486] The 120th target gene is the hsa-miR-8071 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0487] The 121st target gene is the hsa-miR-3648 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0488] The 122nd target gene is the hsa-miR-4732-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0489] The 123rd target gene is the hsa-miR-4787-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0490] The 124th target gene is the hsa-miR-3917 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0491] The 125th target gene is the hsa-miR-619-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0492] The 126th target gene is the hsa-miR-1231 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0493] The 127th target gene is the hsa-miR-342-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0494] The 128th target gene is the hsa-miR-4433a-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0495] The 129th target gene is the hsa-miR-6766-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0496] The 130th target gene is the hsa-miR-4707-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0497] The 131st target gene is the hsa-miR-7114-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0498] The 132nd target gene is the hsa-miR-6872-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0499] The 133rd target gene is the hsa-miR-6780b-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0500] The 134th target gene is the hsa-miR-7845-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0501] The 135th target gene is the hsa-miR-6798-3p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0502] The 136th target gene is the hsa-miR-665 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0503] The 137th target gene is the hsa-miR-6848-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0504] The 138th target gene is the hsa-miR-5008-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0505] The 139th target gene is the hsa-miR-4294 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0506] The 140th target gene is the hsa-miR-6511a-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0507] The 141st target gene is the hsa-miR-4435 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0508] The 142nd target gene is the hsa-miR-4747-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0509] The 143rd target gene is the hsa-miR-6880-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0510] The 144th target gene is the hsa-miR-6869-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0511] The 145th target gene is the hsa-miR-7150 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0512] The 146th target gene is the hsa-miR-1260a gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0513] The 147th target gene is the hsa-miR-6877-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0514] The 148th target gene is the hsa-miR-6721-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0515] The 149th target gene is the hsa-miR-4656 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0516] The 150th target gene is the hsa-miR-1229-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0517] The 151st target gene is the hsa-miR-4433a-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0518] The 152nd target gene is the hsa-miR-4274 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0519] The 153rd target gene is the hsa-miR-4419b gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0520] The 154th target gene is the hsa-miR-4674 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0521] The 155th target gene is the hsa-miR-6893-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0522] The 156th target gene is the hsa-miR-6763-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0523] The 157th target gene is the hsa-miR-6762-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0524] The 158th target gene is the hsa-miR-6738-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0525] The 159th target gene is the hsa-miR-4513 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0526] The 160th target gene is the hsa-miR-6746-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0527] The 161st target gene is the hsa-miR-6880-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0528] The 162nd target gene is the hsa-miR-4736 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0529] The 163rd target gene is the hsa-miR-718 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0530] The 164th target gene is the hsa-miR-6717-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0531] The 165th target gene is the hsa-miR-7847-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0532] The 166th target gene is the hsa-miR-760 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0533] The 167th target gene is the hsa-miR-1199-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0534] The 168th target gene is the hsa-miR-6813-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0535] The 169th target gene is the hsa-miR-6769a-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0536] The 170th target gene is the hsa-miR-1193 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0537] The 171st target gene is the hsa-miR-7108-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0538] The 172nd target gene is the hsa-miR-6741-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0539] The 173rd target gene is the hsa-miR-4298 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0540] The 174th target gene is the hsa-miR-6796-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0541] The 175th target gene is the hsa-miR-4750-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0542] The 176th target gene is the hsa-miR-6785-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0543] The 177th target gene is the hsa-miR-1292-3p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0544] The 178th target gene is the hsa-miR-4749-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0545] The 179th target gene is the hsa-miR-6800-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0546] The 180th target gene is the hsa-miR-4722-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0547] The 181st target gene is the hsa-miR-4746-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0548] The 182nd target gene is the hsa-miR-4450 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0549] The 183rd target gene is the hsa-miR-6795-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0550] The 184th target gene is the hsa-miR-365a-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0551] The 185th target gene is the hsa-miR-498 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0552] The 186th target gene is the hsa-miR-6797-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0553] The 187th target gene is the hsa-miR-1470 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0554] The 188th target gene is the hsa-miR-6851-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0555] The 189th target gene is the hsa-miR-1247-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0556] The 190th target gene is the hsa-miR-5196-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0557] The 191st target gene is the hsa-miR-208a-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0558] The 192nd target gene is the hsa-miR-6842-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0559] The 193rd target gene is the hsa-miR-150-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0560] The 194th target gene is the hsa-miR-4534 gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0561] The 195th target gene is the hsa-miR-3135b gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0562] The 196th target gene is the hsa-miR-3131 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0563] The 197th target gene is the hsa-miR-4792 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0564] The 198th target gene is the hsa-miR-6510-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0565] The 199th target gene is the hsa-miR-504-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0566] The 200th target gene is the hsa-miR-3619-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0567] The 201st target gene is the hsa-miR-671-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0568] The 202nd target gene is the hsa-miR-4667-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0569] The 203rd target gene is the hsa-miR-4430 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0570] The 204th target gene is the hsa-miR-3195 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0571] The 205th target gene is the hsa-miR-3679-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0572] The 206th target gene is the hsa-miR-6076 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0573] The 207th target gene is the hsa-miR-6515-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0574] The 208th target gene is the hsa-miR-6820-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0575] The 209th target gene is the hsa-miR-4634 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0576] The 210th target gene is the hsa-miR-187-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0577] The 211th target gene is the hsa-miR-6763-5p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0578] The 212th target gene is the hsa-miR-1908-3p gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0579] The 213th target gene is the hsa-miR-1181 gene, its congeners, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0580] The 214th target gene is the hsa-miR-6782-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript can serve as a marker for ovarian tumors.

[0581] The 215th target gene is the hsa-miR-5010-5p gene, its homologs, their transcripts, or their variants or derivatives. To date, there are no known r...

Claims

1. A kit for detecting ovarian tumors, comprising a nucleic acid that can specifically bind to the ovarian tumor marker miR-675-5p polynucleotide, or a polynucleotide consisting of a complementary chain of said polynucleotide.

2. The kit according to claim 1, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (a) to (e) below: (a) (1) A polynucleotide consisting of the base sequence represented by Sequence ID No. 113 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases, (2) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (1), (3) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (1), (4) any polynucleotide or fragment thereof containing modified nucleic acids and / or modified nucleotides, (b) A polynucleotide containing the base sequence represented by Sequence ID No. 113 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (c) (5) A polynucleotide consisting of a base sequence represented by Sequence ID No. 113 or a base sequence complementary to the base sequence in said base sequence where u is t, or a fragment thereof containing 15 or more consecutive bases. (6) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (5), (7) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (5), (8) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (d) A polynucleotide containing a nucleotide sequence represented by Sequence ID No. 113 or a nucleotide sequence complementary to the nucleotide sequence in said sequence where u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (e) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (a) to (d) above under stringent conditions.

3. Said kit comprises another ovarian tumor marker, miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3p,miR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-12225-3p、miR-6132、miR-4734、miR-31194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-71114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-65111a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-119-5p、miR-6813-5p、miR-6769a-5p、mi R-11193、miR-71108-3p、miR-67411-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、a group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p,The kit according to claim 1 or 2, further comprising a nucleic acid that can specifically bind to at least one polynucleotide selected from the group consisting of and miR-22-3p, or a polynucleotide consisting of a complementary chain of said polynucleotide.

4. The kit according to claim 3, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (f) to (j) below: (f) (9) A polynucleotide consisting of a base sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (10) (9) Polynucleotides or fragments thereof, the base sequence of which includes the deletion, substitution, addition or insertion of one or two bases, (11) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (9), (12) any polynucleotide or fragment thereof from (9) to (11) including modified nucleic acids and / or modified nucleotides, (g) A polynucleotide containing a base sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (h) (13) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (14) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (13), (15) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (13), (16) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (i) A polynucleotide containing a nucleotide sequence represented by any of SEQ ID NOs: 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (j) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (f) to (i) above under stringent conditions.

5. A device for detecting ovarian tumors, comprising a nucleic acid capable of specifically binding to the ovarian tumor marker miR-675-5p polynucleotide, or a polynucleotide consisting of a complementary chain of said polynucleotide.

6. The device according to claim 5, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (a) to (e) below: (a) (1) A polynucleotide consisting of the base sequence represented by Sequence ID No. 113 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases, (2) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (1), (3) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (1), (4) any polynucleotide or fragment thereof containing modified nucleic acids and / or modified nucleotides, (b) A polynucleotide containing the base sequence represented by Sequence ID No. 113 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (c) (5) A polynucleotide consisting of a base sequence represented by Sequence ID No. 113 or a base sequence complementary to the base sequence in said base sequence where u is t, or a fragment thereof containing 15 or more consecutive bases. (6) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (5), (7) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (5), (8) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (d) A polynucleotide containing a nucleotide sequence represented by Sequence ID No. 113 or a nucleotide sequence complementary to the nucleotide sequence in said sequence where u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (e) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (a) to (d) above under stringent conditions.

7. Said device is characterized in that miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3p, which are other ovarian tumor markers,miR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-12225-3p、miR-6132、miR-4734、miR-31194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-71114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-65111a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-119-5p、miR-6813-5p、miR-6769a-5p、mi R-11193、miR-71108-3p、miR-67411-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、a group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p,The device according to claim 5 or 6, further comprising a nucleic acid that can specifically bind to at least one polynucleotide selected from the group consisting of and miR-22-3p, or a polynucleotide consisting of a complementary chain of said polynucleotide.

8. The device according to claim 7, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (f) to (j) below: (f) (9) A polynucleotide consisting of a base sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (10) (9) Polynucleotides or fragments thereof, the base sequence of which includes the deletion, substitution, addition or insertion of one or two bases, (11) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (9), (12) any polynucleotide or fragment thereof from (9) to (11) including modified nucleic acids and / or modified nucleotides, (g) A polynucleotide containing a base sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (h) (13) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (14) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (13), (15) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (13), (16) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (i) A polynucleotide containing a nucleotide sequence represented by any of SEQ ID NOs: 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (j) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (f) to (i) above under stringent conditions.

9. The device according to any one of claims 5 to 8, wherein the device is a device for measurement by hybridization technology.

10. The device according to claim 9, wherein the hybridization technology is nucleic acid array technology.

11. A method for supporting the detection of ovarian tumors, comprising measuring the expression level of the ovarian tumor marker miR-675-5p polynucleotide in a subject's sample, and using the measured expression level to evaluate in vitro whether the subject has or does not have an ovarian tumor, The aforementioned evaluation is a method of evaluation support based on the results of in vitro tests, not a judgment by a physician.

12. A method for assisting the detection of ovarian tumors, comprising using a polynucleotide of miR-675-5p, which is an ovarian tumor marker, or a nucleic acid that can specifically bind to a polynucleotide consisting of a complementary strand of said polynucleotide, or using a kit according to any one of claims 1 to 4 or a device according to any one of claims 5 to 10 that contains said nucleic acid to measure the expression level of the target nucleic acid miR-675-5p in a subject's sample, and evaluating in vitro whether the subject has an ovarian tumor or not using the measured expression level and the similarly measured control expression level of a healthy person, The aforementioned evaluation is a method of evaluation support based on the results of in vitro tests, not a judgment by a physician.

13. A method for supporting the detection of ovarian tumors, comprising using a polynucleotide of miR-675-5p, which is an ovarian tumor marker, or a nucleic acid that can specifically bind to a polynucleotide consisting of a complementary strand of said polynucleotide, or using a kit according to any one of claims 1 to 4 or a device according to any one of claims 5 to 10 that includes said nucleic acid, measuring the expression level of a target gene, which is the miR-675-5p gene, in a sample from a subject; substituting the expression level of the target gene in the sample from the subject into a discriminant formula, which is created using the gene expression levels of a sample from a subject known to have an ovarian tumor and the gene expression levels of a sample from a subject not affected by an ovarian tumor as training samples, and which is capable of distinguishing between the presence or absence of an ovarian tumor, thereby evaluating the presence or absence of an ovarian tumor in vitro, The aforementioned evaluation is a method of evaluation support based on the results of in vitro tests, not a judgment by a physician.

14. The method according to claim 12 or 13, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (a) to (e) below: (a) (1) A polynucleotide consisting of the base sequence represented by Sequence ID No. 113, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (2) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (1), (3) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (1), (4) any polynucleotide or fragment thereof containing modified nucleic acids and / or modified nucleotides, (b) A polynucleotide containing the base sequence represented by Sequence ID No. 113 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (c) (5) A polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence represented by Sequence ID No. 113, or a nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (6) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (5), (7) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (5), (8) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (d) A polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence represented by Sequence ID No. 113, or a nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (e) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (a) to (d) above under stringent conditions.

15. miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3p, which are other ovarian tumor markers,miR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-12225-3p、miR-6132、miR-4734、miR-31194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-71114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-65111a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-119-5p、miR-6813-5p、miR-6769a-5p、mi R-11193、miR-71108-3p、miR-67411-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、the group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p,The method further includes measuring the expression level of at least one polynucleotide selected from the group consisting of and miR-22-3p in the subject's sample, and using the measured expression level in combination with the expression level of miR-675-5p in the subject's sample to perform the in vitro evaluation described above. The aforementioned evaluation is not a judgment by a physician, but rather an evaluation support based on the results of in vitro tests. The method according to any one of claims 11 to 14.

16. The method according to claim 15, wherein the expression level of the at least one polynucleotide in a subject's sample is measured using a nucleic acid that can specifically bind to each of the at least one polynucleotide or a polynucleotide consisting of a complementary chain of said polynucleotide, and the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof shown in (f) to (j) below: (f) (9) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (10) (9) Polynucleotides or fragments thereof, the base sequence of which includes the deletion, substitution, addition or insertion of one or two bases, (11) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (9), (12) Polynucleotides or fragments thereof of (9) to (11) including modified nucleic acids and / or modified nucleotides, (g) A polynucleotide containing a base sequence represented by any of sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (h) (13) A polynucleotide consisting of a nucleotide sequence complementary to any of the nucleotide sequences represented by sequence numbers 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (14) A polynucleotide or fragment thereof having a deletion, substitution, addition or insertion of one or two bases in the base sequence of the polynucleotide or fragment thereof of (13), (15) A polynucleotide or fragment thereof that exhibits 90% or more % identity with the base sequence of the polynucleotide or fragment thereof of (13), (16) any polynucleotide or fragment thereof comprising modified nucleic acids and / or modified nucleotides, (i) A polynucleotide containing a nucleotide sequence complementary to any of the nucleotide sequences represented by SEQ ID NOs: 1-10, 12-36, 38-80, 82-112, and 114-275, or a nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (j) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (f) to (i) above under stringent conditions.

17. The method according to any one of claims 11 to 16, wherein the subject is a human.

18. The method according to any one of claims 11 to 17, wherein the specimen is blood, serum, or plasma.

Images